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Abstract——Amylin is a pancreatic b-cell hormone
that produces effects in several different organ systems.
Here, we review the literature in rodents and in humans
on amylin research since its discovery as a hormone
about 25 years ago. Amylin is a 37-amino-acid peptide
that activates its specific receptors, which are
multisubunit G protein–coupled receptors resulting
from the coexpression of a core receptor protein with
receptor activity–modifying proteins, resulting in
multiple receptor subtypes. Amylin’s major role is
as a glucoregulatory hormone, and it is an important
regulator of energy metabolism in health and disease.
Other amylin actions have also been reported, such as on
the cardiovascular system or on bone. Amylin acts
principally in the circumventricular organs of the
central nervous system and functionally interacts
with other metabolically active hormones such as
cholecystokinin, leptin, and estradiol. The amylin-based
peptide, pramlintide, is used clinically to treat type 1 and
type 2 diabetes. Clinical studies in obesity have shown
that amylin agonists could also be useful for weight loss,
especially in combination with other agents.
ABBREVIATIONS: 5CNAC-sCT, N-(5-chlorosalicyloyl)-8-aminocaprylicacid; AD, Alzheimer’s disease; AP, area postrema; BAT, brown
adipose tissue; BMI, body mass index; CCK, cholecystokinin; CeA, central amygdala; CGRP, calcitonin gene–related peptide; DBH, dopamine-
b-hydroxylase; DIO, diet-induced obese; ERK1/2, extracellular signal–regulated kinase 1 and 2; GLP-1, glucagon-like peptide 1; GPCR,
G protein–coupled receptor; LPB, lateral parabrachial nucleus; MC, melanocortin; NTS, nucleus of the solitary tract; OVX, ovariectomized;
PEG, polyethylene glycol; RAMP, receptor activity–modifying protein; SFO, subfornical organ; STAT3, signal activator of transcription 3;
U0126, 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene; UCP, uncoupling protein; VBS, visible burrow system; VMH,
ventromedial hypothalamus; VTA, ventral tegmental area.
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I. Introduction
Since its discovery in 1986, the hormone known as
amylin has been the subject of extensive research that
has ultimately translated into the approved diabetes drug
pramlintide acetate (Symlin; AstraZeneca, Wilmington,
DE). A timeline that outlines some of the major
discoveries and important achievements in this field is
presented in Fig. 1. Pramlintide is an analog of amylin,
which has been developed as a therapeutic for the
treatment of both type 1 and type 2 diabetes mellitus.
Although the currently approved therapeutic indications
for amylin agonists are in the diabetes space, the bulk of
research into amylin biology over the past decade relates
to its actions as a satiation hormone. This review covers
historical aspects of amylin discovery, receptors, and
physiology. In particular, we focus on amylin’s well
characterized effects on eating and weight regulation,
with coverage of supporting pharmacology studies in
preclinical and clinical studies. The prospect of combi-
nation therapies using amylin agonists is also covered
in depth. The well established and emerging actions of
amylin are summarized in Fig. 2 to provide an overview
of its physiologic functions.
II. Amylin
A. Amylin and Related Peptides
Amylin, also known as islet/insulinoma amyloid
polypeptide or diabetes-associated peptide, is a 37-amino-
acid secreted hormone (Fig. 3), derived from an 89-amino-
acid precursor (Westermark et al., 2011). The processing
of the prohormone to yield amylin occurs via carboxy-
peptidase E and prohormone convertases 1/3 and 2
(Westermark et al., 2011). The gene encoding this peptide
is found on chromosome 12 in humans (12p12.1). Two
major post-translational modifications are required for
full bioactivity; these are a C-terminal amide (Tyr37) and
a disulfide bond formed between the two cysteine residues
found at positions 2 and 7 (Fig. 3) (Young et al., 1996b). In
terms of amino acid sequence, amylin is most closely
related to calcitonin gene–related peptide (CGRP). CGRP
also shares a similarly positioned disulfide bond and an
Fig. 1. A timeline of major discoveries and achievements in the field of
amylin biology. Effects where convincing evidence for a physiologically or
pathophysiologically relevant role of amylin exists are marked with an
asterisk.
Fig. 2. An overview of the major actions of amylin. Amylin, secreted from
the pancreas after a meal, circulates in the blood to activate specific
receptors in the brainstem. This results in suppression of glucagon release
from the pancreas, a reduction in food intake, and gastric emptying. The net
effect of these actions is to decrease blood glucose, associated with longer-
term reductions in body weight. The most well established effects of amylin
are shown in the box with a solid line. Less well defined effects of amylin are
shown in the dashed box.
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amidated C terminus. This is also the case for calcitonin,
adrenomedullin, and adrenomedullin 2. Together, these
peptides form a small family, united by these charac-
teristic features. Consequently, there is a degree of overlap
in binding the cognate receptors for each peptide and
pharmacological activity.
Commonalities and differences in amino acid se-
quence and pharmacology between these peptides and
across species have been used to develop agonists or
antagonists that mimic or block amylin activity. The
most notable of these is pramlintide, which is a rela-
tively stable, bioactive synthetic analog of human
amylin. Pramlintide is at least as potent as human
amylin and is an amylinomimetic agent. It is also
a 37-amino-acid polypeptide and differs in amino acid
sequence from human amylin by replacement of amino
acids with proline at positions 25 (alanine), 28 (serine),
and 29 (serine) (Fig. 3). As a result of these sub-
stitutions, pramlintide is soluble, nonadhesive, and
nonaggregating, thereby overcoming a number of the
Fig. 3. Amino acid sequences of amylin and related peptides. The disulfide bond between N-terminal cysteine residues is indicated as a dashed line.
All peptides have a C-terminal amide (NH2) and some are acetylated at the N terminus (Ac). Human amylin (hAmy) is colored blue and conserved
residues between hAmy and other peptides are in bold. Rat amylin (rAmy) is yellow, salmon calcitonin (sCT) is green, and human calcitonin (hCT) is
orange. Many peptides are chimeras, as indicated by the coloring.
TABLE 1
Summary of clinically relevant or commonly used amylin-related peptides and their effects
Sequences are shown in Fig. 3.
Peptide Alternative Names Agonist/Antagonist Pharmacology
Pramlintide Symlin, tripro-amylin
(human), [Pro25,28,29]amylin
(human), AC137
Agonist Modified human amylin that lacks amyloidogenic properties; approved in
the United States for clinical treatment of type 1 and type 2 diabetes;
exhibits similar pharmacology and pharmacokinetic properties to
nonamyloidogenic rat amylin. Pharmacology at molecularly defined
amylin receptors shows close similarity to human and rat amylin
(Gingell et al., 2014)
Davalintide AC2307 Agonist Longer-acting amylin agonist optimized for therapeutic treatment of
obesity (Mack et al., 2010). Binds with high affinity to rat nucleus
accumbens amylin and calcitonin receptors. Pharmacology at
molecularly defined amylin receptors has not been reported
AC187 Antagonist Used as a pharmacological tool to block endogenous actions of amylin.
Receptor pharmacology studies show that this peptide can antagonize
both calcitonin and amylin receptors (Hay et al., 2005)
AC253 [Arg4,11]AC187 Antagonist Similar to AC187, AC253 has been used to block endogenous actions of
amylin (Mather et al., 2002). Receptor pharmacology studies show that
this peptide can antagonize rat nucleus accumbens amylin and
calcitonin receptors. Pharmacology at molecularly defined amylin
receptors has not been reported
Salmon
calcitonin 8-32
AC66 Antagonist Used as a pharmacological tool to block endogenous actions of amylin.
Receptor pharmacology studies show that this peptide can antagonize
both calcitonin and amylin receptors (Hay et al., 2005)
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physicochemical liabilities of native human amylin
(Janes et al., 1996; Young et al., 1996b). Pramlintide
exhibits similar biologic activity to that of amylin.
Additional peptides are described in section III.B as
well as in Fig. 3 and Table 1.
B. Amylin Expression, Secretion, and Metabolism
The b-cells found within the islets of Langerhans of
the pancreas are the most well known site for amylin
production. The discovery of amylin was made here, in
the form of amyloid fibrils observed in patients with
type 2 diabetes and in diabetic cats (Westermark et al.,
1986, 1987a,b; Cooper et al., 1987). The pathophysiolog-
ical role of amylin-containing fibrils has received much
attention and was recently reviewed (Westermark et al.,
2011; Abedini and Schmidt, 2013). Therefore, these
fibrils will not be considered further in this review. It is
the activity of amylin as a physiologically important
circulating hormone that warrants this review.
The isolated-perfused pancreas, primary islets, or
b-cell models have shown that amylin secretion can be
stimulated by many factors, including glucose, argi-
nine, and fatty acids, and that amylin secretion tracks
insulin secretion (Kanatsuka et al., 1989; Ogawa et al.,
1990; Qi et al., 2010). Pancreatic b cells are the major
source of circulating plasma amylin, which ranges from
3–5 pM in the fasting state to postprandial concen-
trations of 15–25 pM (Lutz, 2006; Boyle et al., 2011).
Consequently, amylin is cosecreted with insulin in
a consistent molar ratio of approximately 15:1 (insulin:
amylin). In a study of healthy women, an oral glucose
load produced a significant rise in plasma amylin
within 15 minutes. Fasting decreased plasma amylin
concentrations (Hwang et al., 2008). Consistent with
the concept of an elegant and multifactorial hormonal
control system that controls metabolism, the incretin
glucagon-like peptide 1 (GLP-1) can increase plasma
amylin concentrations in healthy subjects (Asmar
et al., 2010). Meal-associated fluctuations of circulating
amylin levels are thought to directly reflect changes in
b-cell secretion; the contribution of other amylin
secreting cells to circulating amylin levels is considered
minor. Furthermore, fluctuations in b-cell secretion,
like the increases observed during the postprandial
period, are believed to elicit the physiologic effects of
amylin on eating and energy homeostasis (Lutz, 2010).
Changes in circulating concentrations of amylin in
obesity are covered later in this review. It is unclear
whether amylin synthesis and secretion (either at
baseline or postprandially) are altered by age because
this aspect has not been studied systematically. The
same is true for amylin’s effects across different age
ranges, but amylin’s effect on eating has been shown to
be present in young and old rats (Lutz et al., 1994).
Additional sites of amylin gene expression are neuro-
endocrine cells of the mammalian stomach (including
humans), the dorsal root ganglion (Gebre-Medhin et al.,
1998b; Tingstedt et al., 1999; Zaki et al., 2002), and the
developing kidney (Wookey et al., 1998). Detailed in-
formation about the function of amylin derived from these
sources is not available. However, given the important
effects of amylin on food intake and gastric emptying, the
intriguing observation that amylin binding sites (see
sections III and V) are also present in the stomach
warrants further investigation.
Amylin and pramlintide both have a circulating
plasma half-life of approximately 13 minutes in rats
after an intravenous bolus injection (Young, 2005d).
Pramlintide pharmacokinetics is discussed in more
detail in section X.A. As with many secreted peptides,
amylin (and pramlintide) is metabolized primarily via
the kidneys, most likely by proteolytic degradation,
and nephrectomized rats exhibit a marked decrease in
plasma clearance of amylin (Leckström et al., 1997;
Vine et al., 1998a). In vivo, both amylin and pramlin-
tide are rapidly cleaved to their respective des-Lys
metabolites. These N-terminally truncated metabolites
are both fully active as amylin agonists, and they
exhibit similar in vivo potency and efficacy to the full-
length peptides (Center for Drug Evaluation and
Research Approval Package for Application Number
21-332. Clinical Pharmacology and Biopharmaceutics
Review. http://www.accessdata.fda.gov/drugsatfda_docs/
nda/2005/21-332_Symlin%20Injection_biopharmr.pdf).
Other amylin cleavage products are found in plasma,
including amylin17–37, which is likely to be inactive
(Nakazato et al., 1990). It is not clear whether a strategy
to inhibit mechanisms of amylin metabolism would
enhance plasma amylin levels sufficiently as an alter-
native clinical intervention to exogenous amylin agonist
therapy. Approaches to enhancing amylin agonist
circulating half-life are covered in section VIII.D.
III. Amylin Receptors
A. Molecular Composition
Amylin receptors belong to the large superfamily of
cell surface G protein–coupled receptors (GPCRs)
(Poyner et al., 2002). This family is further subdivided;
amylin receptors reside in class B. A prominent feature
of amylin receptors is their close relationship to
calcitonin receptors. This is an important consideration
when interpreting the pharmacology, expression, and
physiologic relevance of amylin receptors.
Some of the earliest attempts to characterize amylin
receptors focused on the observations that amylin
could displace CGRP binding and activate CGRP
receptors in liver membranes or other preparations
that endogenously expressed CGRP receptors. Cross-
reactivity of amylin with CGRP receptors was plausi-
ble because these two peptides share approximately
40% amino acid sequence identity. Much of this early
work has now been disregarded because the concen-
trations of amylin needed to displace CGRP binding
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were often too high for this receptor to be physiologically
relevant to amylin action. However, it may be important
to reconsider some of this work in light of the now-
known molecular identity of amylin receptors (see
section III.B). For instance, a pivotal 1988 study de-
scribing salmon calcitonin–sensitive CGRP receptors,
which we now know were probably amylin receptors, is
an important example of the value of these earlier
studies in understanding amylin receptor biology
(Sexton et al., 1988).
To identify additional candidates for amylin recep-
tors, radioligand binding assays have been developed
to determine the quantity of specific amylin binding in
different tissues (Bhogal et al., 1992; Beaumont et al.,
1993). High levels of amylin binding are present in the
lung, stomach fundus, spleen, and brain. To date,
a similar study has not been conducted in human
tissues.
Further investigation of amylin binding sites in the
brain began to show overlap with calcitonin binding
sites, and dense binding sites are detected in the
nucleus accumbens, the area postrema (AP) of the
brainstem, and the hypothalamus. Subsequent work
showed that amylin could stimulate cAMP production
in cells expressing calcitonin receptors and both amylin
and calcitonin could be cross-linked to calcitonin
receptors (Perry et al., 1997). A crucial observation
was made that amylin did not interact with all cells
that expressed calcitonin receptors and other factors
were probably required for this to occur.
In 1999, two groups reported that the single trans-
membrane spanning receptor activity–modifying pro-
teins (RAMPs) were the answer to this conundrum
(Christopoulos et al., 1999; Muff et al., 1999). Although
the calcitonin receptor does have some affinity for and
can be activated by amylin, the presence of RAMPs can
enhance the binding and potency of amylin to such
a degree that postprandial concentrations of amylin
that are in the picomolar range can produce functional
responses (Tilakaratne et al., 2000). There are three
RAMPs and several splice variants of the calcitonin
receptor; consequently, there are many possible amylin
receptor subtypes with potentially unique pharmacol-
ogy, signaling, and regulation profiles. Another impor-
tant consideration is that there are species differences
in terms of pharmacology and receptor splice variants
(Poyner et al., 2002). There has been no investigation as
to the potential role of amylin receptors in the clearance
and degradation of amylin, and as described in section
III.D, it is not even clear whether amylin receptors are
internalized. Furthermore, whether amylin degradation
at the cellular level is also important as a mechanism to
terminate receptor signaling is not known.
B. Pharmacology
Amylin receptors are heterodimers of the calcitonin
receptor and a RAMP (Fig. 4; Table 2). The calcitonin
receptor represents the core receptor protein that
obtains high-affinity amylin binding properties by
coexpression of one of the three RAMPs in the same
cell (McLatchie et al., 1998; Christopoulos et al., 1999;
Muff et al., 1999). RAMPs alter calcitonin receptor
pharmacology from calcitonin-preferring to amylin-
preferring receptors. The pharmacology of these recep-
tors is summarized in Table 2. RAMPs can regulate the
transport to the cell surface of other receptors with
which they interact, but this is not reported to occur
with the calcitonin receptor (Christopoulos et al., 2003;
Hay et al., 2005). The precise site(s) of interaction
between the calcitonin receptor and RAMPs is not yet
known.
Numerous splice variants of the calcitonin receptor
have been reported, which differ between species
(Sexton et al., 1999). Only a few of these have been
characterized with respect to amylin receptor pharma-
cology; however, on the basis of these observations, it
is likely that their coexpression with RAMPs could
also yield amylin receptors. The most common splice
variant, and the one upon which most research has
focused, is now known as CT(a) (formerly CTR2,
CTRI12), as ratified by the relevant Nomenclature
Committee of the International Union of Pharmacology
(Poyner et al., 2002). This is the insert negative form of
the receptor that has equivalent receptors in humans
Fig. 4. A schematic diagram of the amylin receptors, which are formed by the interaction of the calcitonin receptor with RAMP1, RAMP2, or RAMP3 to
generate the AMY1, AMY2, or AMY3 receptors.
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and rodents. The pharmacology of calcitonin and
amylin receptors is regularly updated as new literature
becomes available via the joint initiative of the
Nomenclature Committee of the International Union
of Pharmacology and the British Journal of Pharma-
cology Guide to Receptors and Channels (http://www.
guidetopharmacology.org).
A complication with the interpretation of many
pharmacological studies of these receptors is that most of
this work has likely used a mixed population of receptors,
encompassing RAMP-coupled calcitonin receptors as well
as calcitonin receptors alone. This means that although
in binding assays human calcitonin has low affinity
for [125I]amylin binding sites, cells transfected with
calcitonin receptors and RAMPs display potent hu-
man calcitonin functional responses. In some in-
stances, the expression of RAMP3 with the calcitonin
receptor results in a reduction in human calcitonin
potency (Armour et al., 1999; Hay et al., 2005). The
explanation for this is not clear but it could involve
a modification to the conformation of the calcitonin
receptor or a reduction in the number of “free” calcitonin
receptors (Armour et al., 1999; Hay et al., 2005). Salmon
calcitonin, on the other hand, has high affinity for
[125I]amylin binding sites.
The prevailing consensus is that the AMY1 receptor
is formed by calcitonin receptors expressed with
RAMP1, generating a receptor with high affinity for
amylin, salmon calcitonin, and CGRP (Poyner et al.,
2002). In the case of the delta 47-splice variant of the
calcitonin receptor, its expression with RAMPs results
in a receptor that is activated with greater potency by
CGRP than amylin (Qi et al., 2013). The formation of
an AMY2 (calcitonin receptor/RAMP2) receptor is
highly dependent on cell background and calcitonin
receptor splice variant (see section III.C on signaling).
The AMY3 receptor (calcitonin receptor/RAMP3) has
high affinity for amylin and salmon calcitonin and
lower affinity for CGRP. Although most studies have
been conducted with rat amylin, a recent report shows
that human amylin and pramlintide have very similar
pharmacology to rat amylin at each receptor complex
(Gingell et al., 2014).
The activity of CGRP at receptors that are classified
as amylin receptors is intriguing and may underlie
some of the difficulties in interpreting early studies of
both CGRP and amylin pharmacology. For example, it
has been suggested that the AMY1 receptor could be
a molecular explanation for reports of a “CGRP2” re-
ceptor (Hay et al., 2008). A key question is what the
physiologic relevance of each amylin receptor subtype is,
and in particular what role the AMY1 receptor might
play in amylin and/or CGRP biology. Furthermore,
salmon calcitonin is often used as an amylin agonist,
but it is also a calcitonin receptor agonist; therefore, in in
vivo studies, its effects may be mediated via both amylin
and calcitonin receptors. Therefore, reference to salmon
calcitonin derivatives as “amylinomimetics” should be
treated with caution because it is not known that
all activities are occurring directly through amylin
receptors.
Antagonists are important tools for determining the
contribution of amylin to a particular physiologic
function or for determining the receptor via which
amylin acts. Several peptides have been reported as
amylin receptor antagonists, including salmon calcito-
nin 8-32 and AC187 (Fig. 3), and they are widely used
in the literature (Table 1). Characterization of these
antagonists at molecularly defined calcitonin and
amylin receptor subtypes shows that they are able to
antagonize both receptor classes and, therefore, should
be used carefully. However, when used at appropriate
concentrations to block the endogenous actions of
amylin, their effects are likely to be specific to amylin
receptors. However, these antagonists do not have
sufficient subtype selectivity to be able to determine
the specific amylin receptor that may be mediating
a given effect (Hay et al., 2005; Bailey et al., 2012).
The mechanism of amylin binding to its receptors is
likely to follow the general scheme of class B GPCRs in
which the peptide C terminus engages with the receptor
extracellular domain, whereas the disulfide ring at the
N terminus triggers receptor activation through en-
gagement with the transmembrane portion of the
receptor (Archbold et al., 2011). However, little is known
about the details of this for amylin specifically and what
the relative role of calcitonin receptor or RAMP is in
peptide engagement. Based on recent crystal structures
of the CGRP and adrenomedullin receptors, it is
anticipated that amylin will bind in the most part to
the calcitonin receptor, with a small contribution from
RAMP (Booe et al., 2015). Studies using RAMP1/RAMP2
TABLE 2
Summary of the pharmacology of calcitonin and amylin receptors
Data are based on Alexander et al. (2013) and Gingell et al. (2014). Note that amylin receptor pharmacology can be
influenced by calcitonin receptor splice variant and cell background (e.g., G protein expression level, expression of other
RAMPs).
Receptor Subunits Agonist Potency Order
CTR CT(a) sCT $ hCT $ rAmy,hAmy,pramlintide,CGRP
AMY1(a) CT(a) + RAMP1 sCT $ rAmy,hAmy,pramlintide $ CGRP . hCT
AMY2(a) CT(a) + RAMP2 Cell-type dependent
AMY3(a) CT(a) + RAMP3 sCT $ rAmy,hAmy,pramlintide . CGRP $ hCT
CTR, calcitonin receptor; h, human; r, rat; s, salmon.
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chimeras and site-directed mutagenesis have clearly
identified that the N terminus of RAMP is important
for peptide interactions (Udawela et al., 2006a,b;
Qi et al., 2008). A specific RAMP1 residue (tryptophan
84) may directly contribute to amylin and CGRP
interactions with the AMY1 receptor (Gingell et al.,
2010; Booe et al., 2015). Some data for CGRP at the
AMY1 receptor show that a conserved threonine at
position 6 in the peptide is essential for receptor
activation (Hay et al., 2014). An alanine analog of
amylin at this position had abolished efficacy in vivo,
implying a similar effect at amylin receptors (Roth
et al., 2008b).
C. Signaling
Most studies of amylin receptor signaling derive
from transfected model cellular studies. These studies
show that RAMPs can influence the ability of the
calcitonin receptor to interact with different G proteins
(Morfis et al., 2008). In terms of molecular mechanisms
of amylin receptor signaling, the RAMP C terminus is
important for defining G protein coupling (Udawela
et al., 2006a,b, 2008). The calcitonin receptor splice
variants also have different capacities to interact with
intracellular signaling molecules (Poyner et al., 2002).
The resulting complexity in amylin receptor signaling
is substantial.
Consistent with amylin receptors containing the core
GPCR, the calcitonin receptor, amylin results in acute
activation of Gs-coupled pathways, resulting in an acute
increase in intracellular cAMP. Gq coupling has also
been reported and acute phosphorylation of extracellu-
lar signal–regulated kinase 1 and 2 (ERK1/2) is also
evident, which may relate to protein kinase C rather
than protein kinase A activation (Morfis et al., 2008).
However, many of these experiments are difficult to
interpret because of the intrinsic ability of amylin to
activate the calcitonin receptor. Therefore, mixed
populations of free and RAMP-complexed calcitonin
receptors, which are likely to exist in many experimen-
tal systems, may be activated simultaneously by amylin
(depending on the concentration applied). Thus, the
precise receptor complex through which amylin results
in activation of a particular signaling pathway is often
unknown. For phosphorylation of ERK1/2 and increases
in intracellular Ca2+, amylin can certainly trigger these
events but interestingly, the potency of amylin only
increases slightly in the presence of RAMP when
measuring these pathways compared with cAMP
(Morfis et al., 2008; Qi et al., 2013). Nevertheless, the
time course of rapid ERK1/2 phosphorylation by amylin
in cells transfected with calcitonin and amylin receptors
is consistent with its time course for activation in AP
neurons (see section VI.B) and osteoclasts (Dacquin
et al., 2004; Morfis et al., 2008; Potes et al., 2012; Qi
et al., 2013). Activation of ERK1/2 is clearly a pathway
that amylin can use, but more work is needed to
determine the precise circumstances under which this
occurs and the mechanism involved. There has been no
specific investigation of whether amylin-induced ERK
activation is G protein dependent or arrestin mediated;
however, the calcitonin receptor can recruit arrestin in
response to human and salmon calcitonin (Andreassen
et al., 2014). Amylin was recently reported to either
increase or decrease ERK and Akt phosphorylation in
dispersed islets, depending on the amylin and glucose
concentration (Visa et al., 2015).
cGMP has also been linked to amylin’s effects in the
AP but has not been studied at defined amylin receptor
subtypes in cell lines (Riediger et al., 2001). Conversely,
cAMP has not been measured in response to amylin in
AP neurons but is the prototypical pathway measured
in transfected cell studies. Therefore, there is still
a great deal of research needed to clarify which
intracellular signals are triggered by amylin within its
target cells, and which of these signals are necessary or
sufficient to mediate amylin’s effects.
D. Regulation
GPCR signaling is carefully regulated to maintain
cellular responsiveness to natural ligands. Acutely, this
can be in the form of receptor phosphorylation, uncou-
pling from signaling proteins, and removal of the
receptor from the cell surface (internalization), followed
by recycling of the receptor back to the cell surface or
degradation of the receptor. In the longer term, such as
in the case of prolonged exposure of the receptor to an
agonist drug, the synthesis of the receptor protein can be
downregulated (Luttrell, 2006). The short- or long-term
regulation of defined amylin receptor subtypes has not
been studied. However, there is evidence that the
calcitonin receptor can be regulated by these mecha-
nisms in a cell- and ligand-dependent manner. The
calcitonin receptor is also subject to downregulation,
influencing the utility of calcitonin agonists as drugs for
bone diseases (Tashjian et al., 1978; Bouizar et al., 1987).
Although it is tempting to infer that amylin receptors
will behave similarly, these processes are highly de-
pendent on cellular context; thus, how the calcitonin
receptor behaves in osteoclasts is unlikely to translate
directly to other cell types, such as AP neurons.
Importantly, although this has not been studied with
the calcitonin receptor, RAMPs are known to alter
receptor fate in terms of regulation; therefore, the
amylin receptors could be regulated quite differently
from the calcitonin receptor alone (Bomberger et al.,
2005a,b). Continuous infusion studies of 3–7 days with
osmotic minipumps in rats and mice show that although
there is a gradual decline in effect on food intake over
time, amylin responsiveness is still evident, suggesting
that receptor responsiveness is maintained under these
conditions and that fluctuations of circulating amylin
levels will still trigger relevant effects (Isaksson et al.,
2005; Roth et al., 2006; Mack et al., 2007; Boyle et al.,
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2011; Olsson et al., 2012). This is also apparent during
conditions of prolonged hyperamylinemia (associated
with hyperinsulinemia), such as type 2 diabetes and/or
obesity, in which administration of exogenous amylin
analogs remains effective to produce both glucoregula-
tory and weight-lowering actions (Boyle et al., 2011).
There is little evidence that responsiveness to pramlin-
tide wanes over time in clinical studies. In fact,
pramlintide (two to three daily injections) consistently
produces significant and durable actions to decrease
body weight in obese patients for up to 12 months (Smith
et al., 2008). Although these changes do plateau in the
mid-single-digit percentage range, whether this reflects
direct receptor desensitization and/or the emergence of
counter-regulatory mechanisms to a weight/calorie-
reduced state is difficult to dissect.
E. Expression and Physiologic Relevance of Amylin
Receptor Subtypes
Although there are many potential amylin receptor
subtypes, discerning which subtype is most relevant
to each action of amylin is a considerable challenge.
A range of factors, including a lack of receptor-selective
pharmacological tools, the heteromeric nature of the
receptors, their discrete neuronal expression, and a
lack of reliable or widely available RAMP antibodies all
contribute to this absence of information. It is also
important to point out that RAMPs have several other
GPCR partners, so their expression is only indicative of
a potential interaction with the calcitonin receptor
(McLatchie et al., 1998; Christopoulos et al., 2003;
Harikumar et al., 2009; Lenhart et al., 2013).
Amylin’s actions are mediated by a membrane-bound
receptor that is present in the AP, the presumed
primary site for most amylin actions (see section VI).
Amylin binds strongly to the AP, and calcitonin receptor
mRNA and protein are reported to be expressed here
(Beaumont et al., 1993; Sexton et al., 1994b; Nakamoto
et al., 2000; Barth et al., 2004; Becskei et al., 2004).
RAMP1, RAMP2, and RAMP3 are all stated to be
present in the AP, but thus far only data from in situ
hybridization studies are available (Ueda et al., 2001;
Stachniak and Krukoff, 2003). Amylin-induced neuronal
activation, as assessed by c-Fos mRNA, colocalizes with
CT(a) and RAMP3 mRNA in the rat AP (Sexton et al.,
1994b; Christopoulos et al., 1995; Barth et al., 2004;
Becskei et al., 2004). Laser capture microscopy will be
useful for demonstrating that all necessary amylin
receptor components are in fact expressed in single AP
neurons or other types of neurons (Le Foll et al., 2015).
This will also be a useful technique for determining
which may be the most relevant amylin receptor
subtype in different brain areas.
However, despite the evidence that all structural
components of functional amylin receptors are present
in the AP and that the AP is necessary for amylin
action (see below), it still remains to be shown that the
calcitonin receptor protein colocalizes with any specific
RAMP in amylin-sensitive AP neurons. Furthermore,
whether site-specific ablation of one of the critical
components of the functional amylin receptor in AP
neurons is sufficient to abolish amylin action has not
been tested. Neural RAMP1 overexpression can aug-
ment amylin activity (see section V.C), suggesting that
the AMY1 receptor subtype could be particularly
important. Calcitonin-sensitive CGRP binding sites in
the AP and nucleus accumbens support this hypothesis
(Sexton et al., 1988). However, the data are insufficient
to make judgement calls about which receptor might be
most effectively targeted with amylin agonists.
Other potential sites of relevance to amylin biology
include the subfornical organ (SFO), nucleus of the
solitary tract (NTS), ventral tegmental area (VTA),
nucleus accumbens, and hypothalamus. Amylin bind-
ing has been reported in each of these brain areas,
accompanied by calcitonin receptor protein and/or
mRNA (Olgiati et al., 1983; Sexton et al., 1994a,b;
Christopoulos et al., 1995; Hilton et al., 1995; Skofitsch
et al., 1995; Nakamoto et al., 2000; Ueda et al., 2001;
Stachniak and Krukoff, 2003; Barth et al., 2004; Becskei
et al., 2004; Eftekhari and Edvinsson, 2011). The
presence of RAMPs and thus functional amylin receptor
subtypes is subject to the same caveats described above.
Nevertheless, the SFO reportedly expresses mRNA for
all three RAMPs, whereas the NTS expresses only low
levels of RAMP2. Hypothalamus expression of RAMP1
and RAMP2 is evident in several nuclei. RAMP2 mRNA
has been reported in the preoptic hypothalamic area,
suprachiasmatic nucleus, paraventricular nucleus, peri-
ventricular nucleus, supraoptic nucleus, arcuate nu-
cleus, ventromedial nucleus, and dorsomedial nucleus.
RAMP1 has been reported in fewer hypothalamic nuclei,
namely the arcuate nucleus, ventromedial nucleus, and
dorsomedial nucleus (Oliver et al., 2001; Stachniak and
Krukoff, 2003). Recently, all three RAMPs were detected
in the ventromedial hypothalamus (VMH) (Le Foll et al.,
2015). In the nucleus accumbens, only RAMP1 has been
reported. The VTA was recently reported to express all
necessary receptor components and is suggested to be
another area of physiologic amylin relevance (Mietlicki-
Baase et al., 2013). All of these are rodent studies. There
is no information on the expression of RAMP2 or
RAMP3 protein in the human brain and there are very
limited data for RAMP1, as a consequence of it being
a subunit of the CGRP receptor, which is a major target
for treating migraine (Edvinsson and Warfvinge, 2013).
There are some primate data for calcitonin receptor
expression, and calcitonin receptor expression was
recently shown in the human brainstem (Walker et al.,
2015). This appeared to overlap with RAMP1 in several
places; however, there was limited colocalization per-
formed. Nevertheless, the coexpression of both proteins
was found in some blood vessels and in the spinal
trigeminal tract (Walker et al., 2015). This is the first
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report of AMY1 receptor expression at the protein level
in human tissues. Overall, the current data are un-
satisfactory due to the challenges outlined in the opening
paragraph of this section, and specific amylin receptor
subtypes cannot be attributed to amylin activities at the
present time.
IV. Genetic Models
A number of transgenic and knockout models have
been used to shed light on the role of amylin and its
cognate receptors. Key findings from these models are
summarized in Table 3 and each model is reviewed
below.
A. Genetic Models of Amylin Deficiency
or Overexpression
Amylin knockout animals have been developed to
study the role of amylin in nutrient (in particular
glucose) metabolism and bone metabolism (Gebre-
Medhin et al., 1998a). These mice were established
on a mixed 129Ola/B6 background in which the amylin
coding sequence in exon 3 of the amylin gene was
replaced by a neomycin resistance cassette. The
specific phenotypes of these amylin-deficient mice that
are not related to amylin’s role in the control of eating
include a lower bone mass due to a higher number of
osteoclasts, and reduced late phase nociception in the
paw formalin test; the latter implies that endogenous
amylin increases the perception of chemical pain
(Table 3), despite findings from pharmacology studies
reporting that amylin agonists can have analgesic
properties (Huang et al., 2010). Furthermore, these
mice had increased insulin secretion and a more rapid
glucose elimination, which may indicate that endoge-
nous amylin exerts an inhibitory tone on insulin
secretion (Gebre-Medhin et al., 1998a).
In the mixed genetic background, male amylin
knockout mice show a slightly higher rate of body
weight gain compared with corresponding wild-type
controls (Gebre-Medhin et al., 1998a). This knockout
model has also been backcrossed onto the C57/Bl6
background strain more commonly used in metabolic
disease studies. As reported by Olsson et al. (2012),
body weight did not differ between knockout and wild-
type animals over a 27-week study. This study also
tracked food intake, meal number, and meal size over
this period and did not report any differences between
groups. In another study, body weight, body composi-
tion, and plasma leptin levels were compared in male
TABLE 3
Summary of amylin-related transgenic and knockout models
Model Genetic Background and Method Reported Effects Reference
Amylin gene
deletion
129Ola/B6 (coding sequence of exon 3) Lower bone mass/increased osteoclasts Gebre-Medhin et al.,
1998a,b
Some reduced nociception
Increased insulin secretion/more rapid glucose
elimination
Transient weight gain
Reduced sensitivity to anorexigenic effects of
CCK
Above mice backcrossed onto C57/Bl6 Transient increase in adiposity in females Turek et al., 2010
Food intake, body weight unchanged (versus
wild type)
Reduced sensitivity to endogenous leptin
Reduced hypothalamic leptin receptor mRNA
Amylin
overexpression
FVB/n (pronuclear microinjection of
construct into fertilized oocytes)
Diabetic Wong et al., 2008
Slight decrease in body weight (likely due to
glycosuria, consequence of diabetes)
Calcitonin receptor
deletion
Unclear. Deletion of exons 6 and 7 of calcr High bone mass, increased bone formation
(normal resorption)
Dacquin et al., 2004
C57/Bl6. Cre-LoxP deletion of exons 13
and 14
Food intake and body weight not well evaluated Davey et al., 2008
C57/Bl6. Cre-LoxP deletion of exons 6
and 7
Increased bone formation Keller et al., 2014
RAMP2 and RAMP3
knockout models
RAMP2 deletion is lethal; haploinsufficiency
results in defects in bone homeostasis
Dackor et al., 2007;
Kadmiel et al.,
2011
RAMP3 knockout models have reduced body
weight with normal food intake
Neuronal RAMP1
overexpression
Multiple lines evaluated Decreased body weight, adiposity and
endogenous leptin
Zhang et al., 2011
Increased energy expenditure and sympathetic
tone
Increased BAT, UCP1, and UCP3
Enhanced sensitivity to exogenous amylin
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and female wild-type and knockout mice maintained
on either a low-fat or high-fat diet (Turek et al., 2010).
With the exception of a modest increase in adiposity in
female knockout mice maintained on the low-fat diet,
there were no consequences of amylin gene deletion;
these results imply that at least in the endogenous
system, mice can compensate for an amylin deficit.
Interestingly, amylin knockout mice on the 129Ola/B6
background differed from control animals in their
interaction with other factors controlling eating, in-
dicating that endogenous amylin may have a facilitating
role for other controls of eating, such as cholecystokinin
(CCK) (Mollet et al., 2003a). Likewise, low-fat–fed
amylin knockout mice on the C57/Bl6 background were
found to be less responsive to exogenous administered
leptin. Leptin-induced p-signal activator of transcription
3 (STAT3) signaling and leptin receptor mRNA expres-
sion were reduced in the ventromedial and arcuate
hypothalamus of amylin knockout mice, and the weight-
lowering effects of minipump-administered leptin were
attenuated (Turek et al., 2010). Together, these studies
suggest a modest role for endogenous amylin in the
overall control of energy balance, most likely via an
effect on eating in interaction with other satiating and
adiposity signals (Lutz, 2010).
Numerous rodent models with overexpression of
human amylin have been generated to investigate the
role of islet amyloid deposition in the destruction of
pancreatic b-cells and the pathophysiology of diabetes
(Westermark et al., 2011). To our knowledge, however,
no detailed studies are available on the effect of amylin
overexpression on eating or body weight. Rats that were
transgenic for the overexpression of human amylin
gained weight comparably until 5 months of age but
then had a slightly lower body weight than wild-type
controls (Butler et al., 2004). The authors argued that
lower body weight may have been a consequence of
energy loss due to the development of glycosuria and
diabetes in the transgenic rats, but no detailed data on
food intake were provided. Hence, reduced eating, which
in principle would be consistent with the effects of
exogenous amylin on eating and body weight, cannot be
excluded. The rather small difference between trans-
genic and control animals may have been due to receptor
desensitization or a redundant system controlling body
weight. Because the major difference in body weight
between amylin knockout and wild-type mice occurred
mainly within the first 3 to 4 months of life, the same
may also hold true for animals overexpressing amylin.
Another recent article with mice that were transgenic for
the overexpression of human amylin did not report data
on eating and body weight (Wong et al., 2008).
B. Genetic Models of Amylin Receptors
Given the heteromeric nature of endogenous amylin
receptors, the phenotypes of both calcitonin receptor–
and RAMP-deficient/overexpressing animals need to be
considered. In neither case can the phenotype be
considered specific to amylin; models of altered calcito-
nin receptor expression will likely exhibit phenotypes
relevant to both calcitonin and amylin, whereas with
RAMPs the phenotype could be relevant to many
hormonal systems.
Several models of altered calcitonin receptor expres-
sion have been generated. Deletion of exons 6 and 7 of
the calcitonin receptor gene calcr results in no viable
offspring (Dacquin et al., 2004). However calcr+/2 mice
were viable with expression of the receptor reduced by
2-fold by quantitative polymerase chain reaction. The
genetic background of these mice was not clear. The
phenotype reported was that of high bone mass due to
increased bone formation, with normal bone resorption
(Dacquin et al., 2004). These mice were cross-bred with
amylin+/2 mice, but neither data on eating nor data on
body weight were reported. Because of the nonidentical
phenotypes of calcr+/2 and amylin-deficient mice, it was
concluded that amylin may act through a receptor other
than the calcitonin receptor. However, studies of this
type are often very difficult to interpret due to the
complicated receptor system and because sites of
calcitonin receptor expression during development are
not identical to those in adulthood, as evident from
human calcitonin receptor/Lacz transgenic mice (Jagger
et al., 2000). Subsequent studies have developed mice
with 94%–100% deletion of the calcitonin receptor, using
the Cre-LoxP system, targeting exons 13 and 14 or exons
6 and 7 (Davey et al., 2008; Keller et al., 2014). There
were no differences in body weight in male or female
mice compared with wild-type mice, although the ages
at which these measurements were taken were not
specified. The first attempt at osteoclast-specific deletion
of the calcitonin receptor resulted in no viable offspring,
using floxed calcitonin receptor mice crossed with
TRACP-Cre mice (Davey et al., 2008). Later, however,
a cross with cathepsin K-Cre transgenic mice resulted in
viable mice. These mice showed increased bone re-
sorption (Turner et al., 2011). Keller et al. (2014) also
developed mice with osteoclast-specific disruption of
calcr, which showed increased bone formation. Although
these models give intriguing insight into the physiologic
role of the calcitonin receptor in bone biology, none of
these models have been carefully evaluated with respect
to food intake, body weight, or sensitivity to diet-induced
obesity.
Knockout models lacking each RAMP have been
generated and their phenotypes were recently summa-
rized (Kadmiel et al., 2012). Most work has focused on
understanding their role in adrenomedullin or CGRP
physiology. RAMP1 and RAMP3 global deletion leads
to viable offspring, whereas loss of RAMP2 is lethal
and therefore heterozygous mice are used to study its
function. In all cases, there are no reports in relation to
glucose homeostasis. Haploinsufficiency of RAMP2
results in defects of bone homeostasis (Kadmiel et al.,
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2011). Only for RAMP3 is a body weight phenotype
reported, whereby there is an age-dependent lean
phenotype at approximately 6 months of age, compared
with wild-type mice. Food and water intake was
apparently unaltered in these animals and the reason
for the difference in body weight is not yet known
(Dackor et al., 2007). Because of the lack of investigation
into parameters relevant to amylin, no conclusions can
be drawn as to the relative importance of each RAMP at
this time.
A few RAMP overexpression models have also
been generated. There is a global human RAMP1-
overexpressing model and a neural-specific human
RAMP1-overexpressing model (Zhang et al., 2007;
Sabharwal et al., 2010). Characterization of the second
of these does potentially provide insight into amylin
physiology and we describe the relevant aspects in
section V.C. There is also a model of RAMP2 over-
expression in smooth muscle, but this is unlikely to
have particular relevance to amylin (Tam et al., 2006).
Overall, the extant literature on RAMP transgenics
has included only a limited investigation of each model
with respect to amylin physiology.
V. Physiology of Amylin’s Effect on Eating
This section focuses on animal studies that have
helped to define the physiologic relevance of amylin,
especially with respect to its action on energy homeo-
stasis. Data are summarized about the effects of amylin
on different aspects of energy homeostasis (i.e., its effect
on eating as a satiating hormone and adiposity signal
and its effect on energy expenditure). Because some
reviews have recently summarized major aspects of
amylin physiology (Lutz, 2012a,b; Young, 2012), this
section focuses mainly on more recent articles that
extend the perspectives previously described.
Amylin is an important regulator of nutrient fluxes
because it reduces energy intake, modulates nutrient
utilization by inhibiting postprandial glucagon secretion,
and increases energy disposal by preventing compensa-
tory decreases of energy expenditure in weight-reduced
individuals. The most investigated function of amylin is
to reduce eating by inducing satiation (the promotion of
meal-ending processes). Whether amylin also influences
satiety (the control of the intermeal interval) has not
been tested formally. Amylin’s satiation effect is thought
to be mainly mediated by stimulation of specific amylin
receptors in the AP. Secondary brain sites to mediate
amylin action include the NTS and the lateral para-
brachial nucleus (LPB), which convey the neural signal
to the lateral hypothalamic area, and other hypotha-
lamic nuclei (Fig. 5). Amylin may also signal the degree
of adiposity because plasma levels of amylin are
increased in adiposity and because higher amylin
concentrations in the brain result in reduced body
weight gain and adiposity, whereas amylin receptor
antagonists increase body adiposity. The central mech-
anisms involved in amylin’s effect on energy expenditure
are much less known. A series of recent experiments in
animals and humans indicate that amylin agonism is
a promising therapeutic option for obesity, especially in
combination with other hormones and/or small molecule
anorectic agents. The most extensive data set is avail-
able for the combination therapy of amylin and leptin.
Ongoing research focuses on the mechanisms of these
interactions.
A. Amylin as a Satiation Signal
One of the most extensively investigated functions of
amylin focuses on its role as a signal of satiation (Lutz,
2010). It is believed that amylin is a physiologic
regulator of meal size (Geary, 2005; Lutz and Geary,
2008). Eating leads to a rapid increase in circulating
amylin levels and exogenous amylin reduces eating
within minutes after application. The effect of amylin in
reducing meal size is dose dependent and the effect is
effectively and specifically blocked by amylin antago-
nism; on the other hand, amylin antagonists alone
increase eating by a meal size effect (Mollet et al., 2004).
Importantly, amylin and its analogs reduce meal size
without producing signs of conditioned taste aversion or
visceral illness (Lutz et al., 1995b; Morley et al., 1997;
Mack et al., 2007, 2010). Overall, the data indicate that
amylin acts as a physiologic short-term satiating hor-
mone in rats.
Reduced drinking that has been observed in some
studies after the administration of exogenous amylin
seems to be secondary to the reduction in eating. No
evidence is available that would support the opposite
conclusion (i.e., that amylin reduces eating secondary
to an effect on water intake) (Lutz et al., 1994; Arnelo
et al., 1996; Morley et al., 1997; Asarian et al., 1998).
Fig. 5. An overview of the neuroaxis involved in mediating amylin’s
eating-inhibitory effect and presumed sites of interaction with other
hormones, shown on a graphical representation of the rat brain.
Peripheral amylin reaches the AP via the blood circulation and activates
AP projection areas such as the NTS and the LPB. Amylin interacts with
CCK, which signals the brain via vagal afferents, and with leptin.
Estradiol modulates amylin’s effect but it is currently unclear whether
this may involve brainstem or hypothalamic structures. ARC, arcuate
nucleus; E2, estradiol.
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B. Amylin as an Adiposity Signal
The concept of “homeostatic eating controls” classi-
cally distinguishes between adiposity or “tonic” signals
that enhance the effect of satiation and other meal-
associated or “episodic” signals; adiposity signals are
secreted in proportion to body adiposity by adipose
tissue (leptin) or the pancreas (insulin, amylin), and
are thought to affect eating by enhancing the effects of
satiation signals. For example, amylin, similar to
leptin and insulin, enhances CCK’s satiating effect
(Riedy et al., 1995; Barrachina et al., 1997; Bhavsar
et al., 1998; Mollet et al., 2003a). Even though the
concept of distinct satiation versus adiposity signals is
an oversimplification of the physiologic situation, it
helps to structure the signals involved in the control of
energy balance. The situation is, however, complicated
by the fact that some signals actually may be part of
both categories; insulin is considered a classic adiposity
signal (Woods, 2005), but it is also released during
meals, and blockade of endogenous insulin by insulin
antibodies increased meal size (Surina-Baumgartner
et al., 1995).
Like insulin, a similar “dual role” may also apply to
amylin; it is released during meals and a number of
experiments suggest a role for amylin as an adiposity
signal. For example, basal plasma levels of amylin are
higher in obese rats than in lean rats (Pieber et al.,
1994), and high-fat–fed obese rats have higher baseline
amylin levels than age-matched lean controls (Boyle
et al., 2010, 2011). However, not all studies showed
such an effect (Gloy et al., 2010) and it is possible that
extended periods of being overweight may be required
(Boyle et al., 2011) for baseline amylin levels to increase
after the onset of obesity. In general, amylin secretion
from the b-cell correlates very tightly with insulin
secretion.
More direct evidence for amylin being an adiposity
signal is provided by experiments showing that chronic
peripheral (Roth et al., 2006; Mack et al., 2007) or central
(Rushing et al., 2001) amylin decreases body weight and
fat gain, whereas amylin antagonists increase body
adiposity (Rushing et al., 2001). Furthermore, centrally
administered amylin levels seem to directly influence
the target body weight of rats (Wielinga et al., 2010).
Together, these data suggest that central amylin, like
leptin or insulin, may encode the regulated level of body
weight and hence may contribute to the relative
constancy of body weight throughout adult life.
Even though the underlying mechanisms are not yet
clear, amylin action shows interesting differences to the
action of CCK, which may be a “pure” satiation signal.
First, rats receiving a continuous infusion of CCK do not
show sustained reductions in eating or body weight
(Crawley and Beinfeld, 1983). Second, CCK given before
each spontaneous meal effectively reduced meal sizes,
but the effect seems to be totally compensated by an
increase in meal frequency (West et al., 1984). Similar
compensations do not occur during chronic amylin
infusions (Lutz et al., 1995b; Arnelo et al., 1996),
perhaps because of the tonic eating-inhibitory effect of
amylin (Grabler and Lutz, 2004). It would be interesting
to know whether tonic and episodic effects of amylin rely
on similar or distinct mechanisms. Both, however, seem
to require an intact AP (Lutz et al., 1998c, 2001).
C. Amylin and Energy Expenditure
In some of the studies mentioned above, chronic
amylin reduced body fat more than in pair-fed controls
(Roth et al., 2006), as also shown in other experiments
(Isaksson et al., 2005). This indicated that amylin
infusions most likely reduced eating and increased
energy expenditure (Mack et al., 2007; Wielinga et al.,
2007, 2010). Hence, amylin shares another similarity
with leptin because it influences energy balance by an
eating and an energy expenditure effect (Isaksson
et al., 2005; Roth et al., 2006; Mack et al., 2007; Osaka
et al., 2008). In our own studies, amylin increased
energy expenditure acutely when given at low doses
into the third cerebral ventricle or directly into the AP
(Wielinga et al., 2008, 2010). Furthermore, the de-
crease in energy expenditure that is the expected
metabolic reaction in weight-reduced rats is prevented
by chronic central amylin infusion (Wielinga et al.,
2007, 2010).
Some questions in respect to amylin’s effect on
energy expenditure remain. First, it is not yet clear
whether the effect is of physiologic relevance because
the role of endogenous amylin in the control of energy
expenditure has not been tested. Second, the site and
neurotransmitter mechanisms of amylin’s actions on
energy expenditure also remain to be determined.
Finally, further studies are necessary to define the
underlying intracellular processes and whether these
are similar to the ones activated in respect to amylin’s
effect on eating (e.g., pERK, cGMP).
Two recent studies provided interesting mechanistic
input on amylin’s effect on energy metabolism (Zhang
et al., 2011; Fernandes-Santos et al., 2013). In rodents,
as well as in humans, total energy expenditure
depends on the thermogenic activity of the brown
adipose tissue (BAT); BAT activity is controlled by the
sympathetic nervous system and heat production relies
on the organ specific expression of uncoupling protein
(UCP)-1. Although earlier studies failed to demon-
strate a clear effect of amylin on the expression of UCP-1
(Roth et al., 2006, 2008c), recent studies indicate that
BAT activity is increased by amylin, that this effect is
mediated by the sympathetic nervous system, and that
the effects are enhanced in transgenic mice that
overexpress RAMP1 of the AMY1 receptor complex
(Zhang et al., 2011; Fernandes-Santos et al., 2013). In
brief, the neuronal overexpression of human RAMP1
led to sensitization of mice to the metabolic effects of
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amylin; human RAMP1 transgenic mice were lighter,
had less fat, had increased energy expenditure and
body temperature, and showed at least temporary
hypophagia compared with control animals (Zhang
et al., 2011). The higher energy expenditure was
mediated by an increased sympathetic tone in efferents
subserving BAT, and this was associated with in-
creased expression of the peroxisome proliferator–
activated receptor g coactivator 1a as well as UCP-1
and UCP-3 (Fernandes-Santos et al., 2013). Although
these studies are presented in the context of amylin,
the potential role of CGRP should also be considered in
any study investigating RAMP1. This is because
RAMP1 can form two high-affinity receptors for CGRP
and CGRP knockout mice are reportedly protected
against diet-induced obesity and have elevated core
body temperature (Walker et al., 2010). It should be
noted that CGRP can also decrease food intake (Lutz
et al., 1998c; Dhillo et al., 2003).
VI. Mechanisms Underlying Amylin Actions
A. Amylin Action in the Brainstem
Several brain areas have high-affinity binding sites
for amylin, as shown by amylin receptor autoradiogra-
phy studies (Sexton et al., 1994b). Amylin binding is
particularly strong in the circumventricular organs
such as the SFO and the AP. Amylin action in the SFO
may be linked to an effect of amylin to increase
drinking (Riediger et al., 1999; Fry et al., 2007) but
whether it is necessary for the expression of amylin’s
effect on eating has not been demonstrated.
In the context of amylin’s effect on energy metabo-
lism, the AP has received the most attention, although
the contribution of other brain areas such as the VTA
should also be considered (see below; Mietlicki-Baase
et al., 2013). A transporter-mediated process may
facilitate the transfer of amylin through the blood–
brain barrier into the brain, also outside of the circum-
ventricular organs (Banks et al., 1995; Banks and
Kastin, 1998). Of note, the primary receptor sites for
the eating-inhibitory effect of centrally administered
amylin have thus far not been studied in great detail.
A large number of independent studies indicate that
the AP plays an important role in mediating effects of
peripheral amylin. Amylin appears to activate AP
neurons by direct humoral action, whereas vagal or
nonvagal afferents do not seem to be involved (Lutz
et al., 1994, 1995a, 1998a,c, 2001; Morley et al., 1994;
Mack et al., 2010). Furthermore, local amylin adminis-
tration into the AP recapitulates peripheral amylin’s
effect, whereas the amylin antagonist AC187 has the
opposite effect; AC187 also abolished the eating-
inhibitory effect of peripheral amylin (Mollet et al.,
2004). The AP also seems to be necessary for amylin’s
action to inhibit gastric emptying (Young et al., 1995;
Gedulin et al., 1997; Wickbom et al., 2008; Mack et al.,
2010; Young, 2005b). Electrophysiological and immuno-
histochemical studies supported a direct influence of
amylin on the AP (Riediger et al., 2001, 2002, 2004;
Potes et al., 2010b, 2012). As discussed in section III of
this article, the receptor components (calcitonin re-
ceptor, RAMPs) necessary for amylin function appear to
be expressed in the AP. The available evidence is not
sufficient to specify which AMY receptor subtype is
particularly important in the AP, or indeed in any part
of the brain or other tissue.
B. Brainstem Mechanisms Mediating
Amylin Signaling
A frequent marker to define stimulus-activated brain
areas is based on the expression of the immediate early
gene product c-Fos (Rowland et al., 1997; Becskei et al.,
2004; Riediger et al., 2004; Mack et al., 2010; Potes et al.,
2010a). It is important to note that c-Fos expression does
not necessarily have a functional correlate for a behav-
ioral effect of the same stimulus (e.g., see Züger et al.,
2013). Nonetheless, c-Fos expression helps define brain
areas that may be involved in responses to the re-
spective stimulus. According to these studies, endoge-
nous and exogenous amylin activates a neuroaxis (see
section VI.D) comprising the AP, the NTS, and the LPB;
activation of the latter areas seems to depend on an
intact AP because the effect is absent in AP lesioned
rats, and hence in rats that also do not eat less after
amylin injection.
Markers that may also be functionally linked to
amylin are the formation of the second messenger cGMP
(Riediger et al., 2001) or the phosphorylation of ERK1/2
(Potes et al., 2012). Local AP injection of a membrane
permeable analog of cGMP decreased eating similar to
amylin by a meal size effect (Mollet et al., 2004).
Furthermore, phosphorylation of ERK occurred rapidly
in neurons carrying the calcitonin receptor after periph-
eral amylin (Lutz et al., 1995b; Potes et al., 2010b), and
the prior administration of U0126 (1,4-diamino-2,3-
dicyano-1,4-bis[2-aminophenylthio]butadiene), an inhib-
itor of ERK phosphorylation, into the fourth brain
ventricle reduced the acute eating inhibitor effect of
amylin under certain experimental conditions (Potes
et al., 2010b, 2012). Hence, cGMP and the ERK cascade
seem to be directly involved in amylin’s anorectic effect
(see also section III.C).
A downstream consequence of amylin-induced acti-
vation of AP neurons seems to be an increased ex-
pression of dopamine-b-hydroxylase (DBH), the key
enzyme in noradrenaline synthesis, and the subse-
quent release of noradrenaline possibly in the NTS or
LPB (Potes et al., 2010c). DBH-positive neurons in the
AP seem to be necessary for peripheral amylin to
reduce eating because a partial chemical lesion of these
neurons was sufficient to abolish the eating-inhibitory
effect of peripheral amylin (Potes et al., 2010c).
Interestingly, the number of amylin-activated neurons
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correlated with the number of remaining noradrener-
gic neurons in the AP, indicating that rats with larger
noradrenergic lesions and hence fewer remaining
DBH-positive neurons also displayed lower numbers
of amylin-activated AP neurons. A recent electrophys-
iological study suggested that glutamatergic neuro-
transmission in the AP seems to play a role in
mediating amylin effects. According to this study,
amylin receptors appeared to be located mainly on
presynaptic glutamatergic terminals connecting to the
AP neurons (Fukuda et al., 2013); the association of
this effect with the effects in AP neurons described
above has not yet been clarified.
C. Amylin-Sensitive Area Postrema Neurons Are
Sensitive to Nutrients
The activity of amylin-sensitive AP neurons seems to
be modulated by nutrients. The first evidence was
provided by electrophysiological in vitro studies that
showed that amylin and glucose coactivate AP neurons
(Riediger et al., 2002); neurons that were activated by
amylin reduced their spontaneous activity in a concen-
tration-dependent manner when exposed to low glu-
cose concentrations. This cosensitivity finds a correlate
in an amylin-mediated effect that is reduced at low
glucose levels; amylin’s effect to reduce the rate of
gastric emptying was absent under hypoglycemic
conditions (Gedulin and Young, 1998). It will be
interesting then to compare amylin’s effects on eating
under euglycemic, hyperglycemic, and hypoglycemic
conditions. Teleologically, the glucose dependence of
amylin’s effects seems plausible because it guarantees
that amylin should not limit the supply of nutrients at
a time when they are urgently needed.
Amino acids have also been shown to modulate
amylin’s effect on eating and, at the cellular level on
the activity of AP neurons. Interestingly, and opposite
of the effect of glucose, amino acids seem to inhibit
rather than activate these amylin responses. We
recently showed that rats exposed to low-protein
(1%–8%) diets reduce eating more when injected with
amylin than rats exposed to a diet with normal protein
content (18%). Similarly, dietary protein seemed to
inhibit rather than to enhance the amylin-induced
c-Fos activation in the AP, and the same was seen in
rats that received parenteral injections of amino acids
(Züger et al., 2013). The mechanisms underlying these
phenomena and the functional implications are not
clear; whether this mechanism is meant to prevent the
intake of amino acid–deficient diets and thus amino
acid imbalance is not clear and has not been tested
because all rats included in these experiments were
protein replete. In the same context, it is also not clear
whether the effects are due to specific amino acids
directly reducing the effect of amylin to activate AP
neurons using AMY receptors themselves or via other
cellular mechanisms. Finally, these studies also indicated
that the effect of amylin to reduce eating and to induce
c-Fos expression may be dissociated under certain
conditions.
D. Neuroaxis Activation by Amylin
The evidence for an important (although perhaps not
the sole [see below]) role of the AP for the mediation of
the eating-inhibitory effect of peripheral amylin is
strong (e.g., Sexton et al., 1994b; Lutz et al., 1998c;
Becskei et al., 2004; Mollet et al., 2004; Mack et al.,
2010; Potes et al., 2010c). The activation of AP neurons
may then trigger the activation of a neuroaxis that
projects rostrally to the forebrain and that includes the
NTS, the LPB, and the central amygdala (CeA) (Lutz
et al., 1998c; Becskei et al., 2007) (Fig. 5). Lesions of
the respective brain areas (AP, NTS, and LPB)
abolished amylin’s effect, and activation (as indicated
by c-Fos) was absent in brain areas rostral to the lesion
(e.g., in the NTS, LPB, and CeA in AP lesioned rats, or
in the CeA in LPB lesioned rats). The direct link
between the respective brain areas was confirmed by
the use of anterograde and retrograde neuronal
tracers; these studies also identified the LPB as the
primary relay between the hindbrain and the hypo-
thalamus, including the lateral hypothalamic area,
where amylin reduces fasting-induced c-Fos expression
(Riediger et al., 2004; Potes et al., 2010a) and the VMH
(Mollet et al., 2003b; Roth et al., 2008a; Turek et al.,
2010). The latter area received more attention in
recent years due to the possible role of the VMH in
mediating the interaction between amylin and leptin
(see section IX.A).
E. Amylin Action in Other Brain Areas
Despite the clear evidence indicating an important
role of the AP in mediating peripheral amylin’s actions,
it also needs to be realized that amylin binding sites
have widespread distribution throughout the brain
(Sexton et al., 1994b), and the same is true for the
expression of the amylin receptor components, the
calcitonin receptor (Becskei et al., 2004) or the RAMPs
(Ueda et al., 2001; Barth et al., 2004). Central amylin
produces very potent effects on eating (e.g., Rushing
et al., 2000; Osaka et al., 2008; Wielinga et al., 2010)
that at least under certain conditions are independent
of an intact AP (Lutz et al., 1998b), and most reports
indicate that lower doses of amylin are required to
reduce eating (and body weight) after infusion into the
lateral or third than in the fourth cerebral ventricle
(Lutz et al., 1997, 1998b; Rushing et al., 2000).
Nonetheless, the physiologic relevance of the eating-
inhibitory effect of central amylin is less clear, because
for most of the potential sites of action, activation by
peripheral amylin has not been demonstrated and it is
also unclear which areas are primarily targeted by
centrally infused amylin. Furthermore, evidence for an
action of centrally produced amylin is scarce and may
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only occur under very specific conditions in females,
which may not be related to effects of amylin on eating
(Dobolyi, 2009).
One interesting study recently provided evidence
that amylin receptors in the VTA may be direct targets
for peripheral amylin. The VTA is well known for its
role in the control of eating and in particular for the
intake of palatable food (Mietlicki-Baase et al., 2013).
That study showed that all amylin receptor com-
ponents are present in the VTA and that direct
administration of the amylin/calcitonin receptor ago-
nist salmon calcitonin into the VTA reduced eating of
normal chow as well as palatable sucrose. Similar to
peripheral amylin (Lutz et al., 1995b) or amylin given
into the AP (Mollet et al., 2004), reduced eating
appeared to result at least in part from a meal size
effect. The authors suggested that amylin may reduce
meal size by modulating the reward value of food
throughout the meal. The observation that adminis-
tration of the antagonist AC187 into the VTA increased
eating and that intra-accumbens AC187 reduced
the effect of peripheral salmon calcitonin on eating
indicates that salmon calcitonin may in fact exert
a direct action on VTA neurons and that the effects
seem to be of physiologic relevance (Mietlicki-Baase
et al., 2013). The relations between the VTA-mediated
effect and the previously described AP-mediated effects
are currently unclear. As noted in section III.C, salmon
calcitonin and AC187 are not selective tools for only
amylin receptors, having activity also at calcitonin
receptors. Therefore, authors must be careful in their
data interpretation using these molecules.
The nucleus accumbens, which also plays a role in
reward/hedonics, has also been tested for its potential
role in the control of food intake by amylin (Kelley,
1999; Baldo and Kelley, 2001). The experiments were
based on the knowledge that the nucleus accumbens
contains a high density of high-affinity amylin binding
sites (Beaumont et al., 1993; Sexton et al., 1994b). In
fact, nucleus accumbens membranes had originally
been used to characterize the properties of amylin
binding sites. It was shown that administration of
amylin into the shell of the accumbens reduced eating
and drinking; however, because amylin also markedly
reduced locomotor activity and because the latter
effects were observed at lower doses than the eating
effect, these motor effects may perhaps be part of an
amylin effect on the “satiety sequence,” which includes
a number of typical postprandial behaviors like rearing
and cleaning. A direct contribution of the nucleus
accumbens to the amylin effect on meal termination
seemed to be less likely (Halford et al., 1998).
F. Summarizing Remarks
Overall, the neuroaxis that is activated by peripheral
amylin or its analogs has been reasonably well defined
(Potes and Lutz, 2010). Evidence for a critical role of
specific hindbrain structures, in particular the AP,
NTS, and LPB, is compelling; activation of these
structures may then affect specific hypothalamic nuclei
(Fig. 5), but their individual roles in the effects of
amylin on eating are still not clear (Potes et al., 2010a;
Trevaskis et al., 2010a; Turek et al., 2010). Further-
more, more studies are required to define the potential
contribution of other circumventricular organs such as
the SFO (Fry et al., 2007; Hoyda et al., 2009; Mimee
et al., 2013). Recent studies indicate that in addition
to the AP, peripheral amylin may activate a more
complex and distributed network that includes the
VTA (Mietlicki-Baase et al., 2013, 2015). However, how
the VTA and the other brain areas may interact is
also not clear. Furthermore, although central amylin
produces potent eating-inhibitory effects, the brain struc-
tures mediating these effects and their relevance under
physiologic conditions are not clear.
VII. Other Actions of Amylin and Potential
Therapeutic Areas
The existence of amylin binding sites and compo-
nents of amylin receptor complexes outside of the
neuroaxis mentioned thus far as well as behavioral
pharmacological studies implicate amylin in other
activities. These suggest alternative potential thera-
peutic areas for intervention with amylin receptor
modulators. Some of these findings were briefly de-
scribed in earlier sections. Overall, the extant litera-
ture surrounding these areas is not as robust as for
amylin’s antidiabetic/obesity effects and is summarized
in Table 4.
A. Amylin in the Cardiovascular System
In general, the majority of amylin’s actions on the
cardiovascular system are believed to be mediated by
activation of CGRP receptors, widely expressed within
the vasculature (for details, see Young, 2005a). These
actions are believed to be largely pharmacological due
to the high plasma concentrations required to observe
a response. Consequently, in rodent models, bolus
intravenous injection of amylin produces a potent
vasodilatation to decrease arterial blood pressure,
accompanied with short-term baroreflex increases in
heart rate (Young et al., 1991). Little work has been
reported investigating how well these actions translate
to human pharmacology. However, it is likely that
clinically relevant doses of pramlintide for treatment of
diabetes or obesity are insufficient to increase plasma
exposure to levels required to activate CGRP receptors
in humans, because it is estimated that the EC50 for
blood pressure lowering exceeds therapeutic pramlin-
tide concentrations by three orders of magnitude.
Confirming this hypothesis, 12-month dosing with
pramlintide in humans did not significantly change
blood pressure (Young et al., 1999).
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Direct cardiac inotropic effects, potentially CGRP
receptor mediated, have been reported for amylin in
isolated rodent cardiomyocytes (Bell and McDermott,
1995), isolated rat hearts (Kaygisiz et al., 2010), and
isolated cardiac tissue from pigs (Saetrum Opgaard
et al., 1999). However, because of the high concen-
trations required to observe efficacy, it is again
unlikely that these actions are clinically relevant at
therapeutic doses.
B. Amylin and Lipolysis
Given the observation that amylin administration
decreases adiposity, the extent to which amylin exerts
direct effects on BAT and white adipose tissue has been
explored. In isolated adipocyte preparations, amylin
stimulates neither lipolysis nor basal or insulin-
stimulated rate of glucose incorporation into either
CO2 or triacylglycerol (Cooper et al., 1988; Lupien and
Young, 1993; Roth et al., 2006). When epididymal fat
pads were excised from amylin-treated animals, the
basal rate of lipolysis did not differ relative to a vehicle-
treated control group. Sustained in vivo administration
of amylin also failed to augment the ex vivo lipolytic
sensitivity of adipose tissue to adrenergic stimulation.
Thus, at least in epididymal fat, amylin did not
regulate basal or stimulated lipolysis. However, more
recent in vitro studies reported that amylin activated
multiple intracellular pathways in human adipose
tissue such as the STAT3, AMP-activated protein
kinase, Akt, and ERK signaling pathways (Moon
et al., 2011). Of note, these effects were obtained at
very high pharmacological levels of amylin in the
culture media and the physiologic significance of these
findings remains to be determined.
C. Amylin and Maternal Behaviors
Microarray studies detected a marked increase (ap-
proximately 25-fold) in amylin expression within the
preoptic area of the hypothalamus of rat dams (Dobolyi,
2009). These mRNA findings were confirmed by quan-
titative polymerase chain reaction and in situ hybrid-
ization methods. Next, a series of experiments detailed
the time course (during late pregnancy and throughout
lactation) and potential mechanisms for amylin expres-
sion (Szabó et al., 2012). First, mRNA levels remained
elevated as long as the pups were not removed from the
dams. Amylin expression was also induced inmaternally
behaving (sensitized) nonlactating females but not in
nonsensitized nulliparous females or in females that did
not become maternal despite the sensitization pro-
cedure. This phenomenon was sex steroid hormone
independent because ovariectomy had no effects. In
other studies, mothers were also separated from their
pups for 22 hours. On return of the pups, neuronal
activation was found in the mother’s preoptic area, with
a distribution pattern similar to amylin-expressing neu-
rons. The authors hypothesize that amylin may play a
role in the physiologic regulation of maternal adaptations
potentially endocrine and emotive, although these remain
to be formally demonstrated.
TABLE 4
Reported effects of amylin that are not extensively covered in this review and their potential therapeutic area
Potential Therapeutic Area Key Findings References
Depression/anxiety Reduced immobility in forced swim test Roth et al., 2009; Turek et al., 2010
Increased hippocampal neurogenesis
Reduced restraint stress-induced sucrose consumption and
hyperthermia
Reduced marble burying
Memory enhancement Increased retention under conditions of “weak” conditioning but
impaired retention under “strong” conditioning in T-maze
Flood and Morley, 1992; Zhu et al., 2015
Improved learning and memory
AD Decreased brain Ab levels Adler et al., 2014; Zhu et al., 2015
Improved performance in memory and cognition in preclinical
disease models
Increased markers of synaptic formation and decreased markers of
inflammation and oxidative stress within hippocampus
Antipsychotic/schizophrenia Intra-accumbens infusion reversed amphetamine-induced
prepulse inhibition disruption
Baisley et al., 2014
Pain Analgesic effects in models of visceral pain when administered
peripherally
Bouali et al., 1995; Gebre-Medhin et al.,
1998b; Sibilia et al., 2000; Huang et al.,
2010
Antinociceptive effects linked to reduced spinal c-Fos expression
No effects on tail immersion when given centrally
Amylin knockout mice have reduced nociception
Osteoporosis In a streptozotocin (STZ) rat model of diabetic osteopenia, addition
of amylin improved bone indices apparently by both inhibiting
resorption and stimulating bone formation.
Cornish et al., 1998; Horcajada-Molteni et al.,
2000, 2001; Dacquin et al., 2004; Gutierrez-
Rojas et al., 2013
Amylin knockout mice have increased bone resorption (decreased
bone mass/density, trabecular bone volume) but normal
osteoblast and bone formation rates
Osteogenic actions depend on diabetic status (effective in low-dose
STZ type 2 diabetic but not insulin-resistant preclinical models)
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D. Amylin and Stress-Induced Eating
Preclinical findings suggest that amylin agonism
may be beneficial in the treatment of neuropsychiatric
disease (see Table 4). Amylin exerted anxiolytic and
antidepressive effects in several preclinical assays
(reviewed in Roth et al., 2009). In a chronic stress
model, the effects of amylin administration were
assessed in rats that were given access to standard
laboratory chow and sucrose solutions and were also
exposed to daily restraint stress. Vehicle-treated rats
increased their consumption of sucrose and increased
visceral adiposity. By contrast, amylin-treated rats
decreased their stress-induced sucrose consumption
after restraint stress, while maintaining their intake of
standard laboratory chow (Roth et al., 2009). Beneficial
effects have also been noted in other preclinical stress
models. For example, during recovery from social
stress in a visible burrow system (VBS), during which
a dominance hierarchy is formed among the males,
rats display hyperphagia and gain weight preferen-
tially as visceral adipose tissue. By proportionally
increasing visceral adiposity, social stress may con-
tribute to the establishment of metabolic disorder.
Amylin was administered to rats fed ad libitum during
recovery from VBS stress in an attempt to prevent
hyperphagia and the resultant gain in body weight and
fat mass. Amylin treatment reduced food intake,
weight gain, and accumulation of fat mass in male
burrow rats but not in male controls that spent time
housed with a single female rather than in the VBS
(Smeltzer et al., 2012).
E. Antipsychotic-Like Actions of Amylin
Recently, antipsychotic-like actions of amylin were
demonstrated after central injections (Baisley et al.,
2014). Amylin infusion into the accumbens shell, but
not the dorsal striatum, reversed amphetamine-
induced prepulse inhibition without affecting baseline
startle. Prepulse inhibition is a commonly used cog-
nitive test paradigm of the reaction of an organism,
such as a mouse, to “startling” stimuli of different
magnitude, such as a sound (Castagné et al., 2009).
Coinfusion of AC187 blocked the ability of amylin to
normalize amphetamine-induced prepulse inhibition
disruption. These findings suggest that amylin recep-
tors may be a potential target for the development of
putative antipsychotics and future work should explore
the potential utility of systemically administered
amylin in this regard.
F. Amylin and Alzheimer’s Disease
Two recent reports suggest that peripheral treat-
ment with either amylin or pramlintide can have
therapeutic effects in Alzheimer’s disease (AD) (Adler
et al., 2014; Zhu et al., 2015). First, lower amylin levels
were noted among subjects with AD and mild cognitive
impairment compared with the cognitively intact
subjects (Adler et al., 2014). This led the authors to
test whether chronic infusions of the amylin analog
pramlintide would be beneficial in rodent models of
AD. Chronic infusions of pramlintide in the senescence-
accelerated prone mouse (a model of sporadic AD)
improved performance in the novel object recognition
task (assay for memory and cognition). These behavioral
effects were accompanied by increased markers of
synaptic formation and decreased markers of inflam-
mation and oxidative stress within the hippocampus
(Adler et al., 2014). Likewise, both amylin and pram-
lintide administration in a transgenic model of AD
improved learning and memory in the Y-maze and
Morris swim tests. These effects were coupled with
reduced amyloid burden and reduced Ab in brain tissue.
The authors suggest that amylin and pramlintide
enhance the removal of Ab from the brain and its
transfer into the blood, probably through their effects
on cerebral vasculature, and amylin and pramlintide
may represent a novel therapeutic avenue for the treat-
ment of AD. However, more work is needed to de-
termine whether amylin is a beneficial or contributory
factor to AD (Yang and Song, 2013).
G. Amylin in Renal Physiology
The effects of amylin in the kidney have been
overlooked in recent years but amylin has interesting
effects on renal physiology. In the spontaneously
hypertensive rat model, the density of amylin binding
sites was greater before the development of hyperten-
sion, compared with control Wistar-Kyoto rats. As
blood pressure increased with age in the spontaneously
hypertensive rat model group, so too did the density
of amylin binding sites (Wookey et al., 1997). Thus,
amylin and its receptor(s) may contribute to the
development or maintenance of hypertension (Wookey
and Cooper, 1998). Amylin may also act as a growth
factor in the kidney and may control water and sodium
reabsorption (Harris et al., 1997; Wookey et al., 1998).
In anesthetized rats, amylin infusion can also promote
diuresis and natriuresis (Vine et al., 1998b).
VIII. Amylin Therapeutic Applications:
Overview/Rationale
In this section, we consider the effects of amylin
(and its analog pramlintide) in the context of diabe-
tes and obesity, the two therapeutic areas that
the biology we have described in sections I–VI gears
it toward. We describe special features of amylin
physiology in the context of preclinical and clinical
studies that are important for its mechanism of action.
In section X, we specifically describe the clinical trials
conducted with amylin agonists in the context of overall
trial endpoint and therapeutic suitability for diabetes or
obesity.
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A. Diabetes
1. Amylin Secretion in Diabetes. There is an absence
of secretion of b-cell hormones in type 1 diabetes,
whereas b-cell dysregulation in type 2 diabetes (depend-
ing on its severity) can range from mild to severe. Since
insulin’s discovery in 1922, treatment of type 1 and late-
stage type 2 diabetes has consisted of exogenous insulin
dosing in response to glucose measurements. The
concept of using insulin to treat diabetes stems from
replacing the loss of pancreatic b-cell hormone as it is
missing or severely undersecreted in either type 1
diabetes or late-stage type 2 diabetes. Although insulin
monotherapy has been a life-saving strategy for these
insulin-deficient patients, even optimally controlled
patients exhibit glycemic hypervariability in response
to relatively modest perturbations in fuel balance. One
of the main reasons that insulin therapy is not adequate
in the treatment of diabetes is the fact that we now
recognize that diabetes is not as simple as a b-cell
failure disease or a monohormonal (insulin) disease. It
is becoming more widely appreciated that adjunctive
therapies that enable reductions in exogenous insulin
are quite desirable. For example, in a percentage of
patients with type 1 diabetes (approximately 12%–40%)
(McGill et al., 2008), long-term insulin monotherapy is
associated with development of metabolic syndrome.
This is felt to be mediated by inducing a persistent state
of hyperinsulinemia wherein exogenous insulin is
circulating in blood at higher concentrations than is
needed at target tissues. In turn, individuals that
develop metabolic syndrome are at an increased risk
for developing clinical microvascular and macrovascular
complications and mortality. One rational candidate for
adjunctive therapy with insulin would be its partner
hormone amylin, which is also deficient in type 1
diabetes and is secreted from the pancreatic b-cell in
a fixed molar ratio with insulin (Young, 2005d). One
study investigated the role in humans of endogenous
amylin to regulate b-cell function The investigators
treated patients with the amylin receptor antagonist,
AC253, generating data that support an endogenous
role of amylin to regulate insulin under certain conditions
and/or disease states (Mather et al., 2002).
2. Postprandial Hyperglucagonemia and Diabetes.
As noted above, the optimal treatment of diabetes
requires more than insulin replacement because of the
involvement of multiple hormonal systems involved in
maintaining tight glycemic control. Juxtaposed to
insulin/amylin-containing pancreatic b-cells are a-cells
that release glucagon to maintain blood glucose levels
at the appropriate concentration (Young, 2005c). In
individuals without diabetes, glucagon prevents hypo-
glycemia by causing the liver to convert stored
glycogen into glucose, which is released into the
bloodstream. As part of an elegant feedback system,
glucagon also stimulates the release of insulin, which
enables glucose to be taken up and used by insulin-
dependent tissues and then insulin in turn also acts
directly upon a-cells to suppress glucagon release.
However, in patients with diabetes, a-cells are de-
prived of insulin signaling, leading to abnormally high
glucagon concentrations (Young, 2005c). It is especially
notable that during the postprandial period, not only is
glucagon abnormally high, but it is paradoxically
elevated in response to food intake, in turn further
contributing to postprandial hyperglycemia. Although
exogenous insulin replacement ultimately stimulates
the a-cells to suppress glucagon, the concentrations of
insulin required also stimulate the liver and muscle,
resulting in a blockade in hepatic glucose production
and increasing peripheral glucose disposal. Collec-
tively, this hormonal milieu contributes to suboptimal
glycemic control.
Glucagonostatic effects of amylin were first demon-
strated in anesthetized rats through the use of an
arginine tolerance test (because amino acids are
a stimulus for glucagon release). These studies re-
vealed that amylin’s effects to suppress glucagon were
quite potent (achieved at an EC50 of 18 pM, which is
in the physiologic range for endogenously secreted
amylin in rats) (Gedulin et al., 1997). Subsequent
rodent studies confirmed a similar profile for the
amylin analog, pramlintide. Interestingly, amylin
antagonism with the amylin receptor antagonist
AC187 increased glucagon levels approximately 2-fold,
implying that amylinergic pathways may exert a tonic
suppression upon glucagon secretion. Amylin’s gluca-
gonostatic properties do not appear to be modulated
via direct effects of amylin upon a-cells because they
are not evident in ex vivo (e.g., isolated-perfused
pancreas) or in vitro studies (e.g., isolated pancreatic
islets; Silvestre et al., 2001). These effects are most
likely mediated via amylin activation of hindbrain
receptors, leading to modulation of vagal efferent
pathways to the pancreas, although this remains to
be demonstrated experimentally. Finally, amylin’s
glucagonostatic effects are not evident in the face of
insulin-induced hypoglycemia (Gedulin et al., 1997;
Nauck et al., 2002). This phenomenon is referred to as
a “hypoglycemic override mechanism” and is a desir-
able feature from a therapeutic perspective.
In patients with type 1 diabetes, postprandial
secretion of glucagon is elevated and was inhibited by
the administration of pramlintide (Nyholm et al., 1999;
Levetan et al., 2003). Pramlintide also prevented the
abnormal meal-related rise in glucagon in insulin-
treated patients with type 1 diabetes (Fineman et al.,
2002). However, although they were evident during
normoglycemia, the glucagonostatic effects of pramlin-
tide were not evident during insulin-induced hypogly-
cemia (Nyholm et al., 1996). Insulin-treated type 2
diabetes also presents with impaired suppression of
glucagon secretion and hepatic glucose production,
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which contribute to unsatisfactory glycemic control. In
this patient group, pramlintide infusions were also
demonstrated to reduce postprandial hyperglucagone-
mia (Nyholm et al., 1999). Hence, the effects of amylin
on glucagon secretion identified in rodents appear to
translate into the clinic to address an important metabolic
derangement in diabetes.
3. Gastric Emptying and Diabetes. A second con-
tributor to the regulation of postprandial glucose levels
is the rate of gastric emptying. Vice versa, gastric
emptying has also been reported to be regulated by
glycemic status; it is slowed by hyperglycemia and
accelerated by hypoglycemia (Horowitz and Fraser,
1994). As such, one potential contributing factor to
increased postprandial glucose excursions in diabetes
could be accelerated gastric emptying despite the clinical
setting of hyperglycemia. Indeed, gastric emptying is
accelerated in some rodent models of type 1 diabetes
(e.g., BioBreeding rats; Plourde et al., 1993; Young et al.,
1995) and streptozotocin-treated rats (Granneman and
Stricker, 1984) and type 2 diabetes (e.g., Zucker Fatty
rats; Green et al., 1997). Hypermotility has also been
noted in clinical studies of individuals with type 1
diabetes (Nakanome et al., 1983) and to a greater extent
type 2 diabetes, especially during its “early” stages
(Jones et al., 1996). However, impaired motility has
not been uniformly observed across clinical studies
(reviewed in Ma et al., 2009). Other than patients with
significant disease and development of significant
gastroparesis, the majority of patients with diabetes
exhibit hypergastric motility in the setting of hypergly-
cemia. Nevertheless, slowing gastric emptying repre-
sents one viable therapeutic strategy for reducing the
rate of postmeal glucose excursions.
In preclinical studies, gastric emptying has been
assessed by quantifying the rate of appearance after
oral delivery of a variety of markers (e.g., phenol red,
acetaminophen, radiolabeled nutrients). Most, but not
all (Lutz et al., 1995b), studies suggested that anorectic
doses of amylin also reduced gastric emptying in rats
and humans (Young et al., 1995; Reidelberger et al.,
2002; Young, 2005b); the effect seemed to be physio-
logically relevant because AC187 accelerated gastric
emptying in rats (Gedulin et al., 2006). Amylin
agonism dose-dependently slowed the rate of gastric
emptying. The effects of rat amylin are quite potent
(ED50 estimated at 0.42 nmol/kg) even in comparison
with other peptidic regulators of nutrient uptake (e.g.,
GLP-1 and CCK have estimated ED50 values of 6.1 and
8.5 nmol/kg, respectively; Young et al., 1996a). Similar
ED50 values in rodents have been obtained with
pramlintide.
At high doses, rat amylin can fully inhibit gastric
emptying in both normal and diabetic rats (Young
et al., 1995). Amylin inhibition of gastric emptying is
thought to be primarily centrally mediated. First,
aspiration of the AP abolishes amylin’s effects on
gastric emptying (Young, 2005b). More recently,
amylin inhibition of gastric emptying was demon-
strated in rats with a subdiaphragmatic vagal deaf-
ferentation (e.g., in which vagal afferent fibers are
destroyed but efferent fibers remain intact), supporting
the hypothesis that amylin acts via hormonal mecha-
nisms to stimulate the AP and transmits signals to the
gut via efferent vagal fibers (Wickbom et al., 2008).
Because the lowest effective amylin doses to reduce
meal size or to slow gastric emptying are comparable
(Reidelberger et al., 2001), it was postulated that
amylin’s effect on gastric emptying contributes to
amylin’s anorectic effect under normal feeding con-
ditions; however, the former effect does not seem to be
necessary for the latter to occur. First, both effects are
pharmacologically distinguishable (Young et al.,
1996a; Young, 1997; Young and Denaro, 1998). Second,
amylin also reduces eating under sham-feeding con-
ditions, hence when gastric and postgastric feedback
signals are eliminated (Asarian et al., 1998). Because
higher doses were necessary to reduce sham feeding
than real feeding (Asarian et al., 1998), amylin may
synergistically interact with other negative feedback
signals to reduce food intake; these may include gastric
feedback (Reidelberger et al., 2001), CCK (Asarian
et al., 1998; Bhavsar et al., 1998; Lutz et al., 2000), and
potentially other signals.
The effects of pramlintide on gastric emptying have
also been assessed in a number of clinical studies.
Infusion of pramlintide delayed solid and liquid gastric
emptying in patients with type 1 diabetes (Kong et al.,
1997), and these effects were subsequently shown to be
dose dependent and no longer evident after 4 hours
(Kong et al., 1998). When the gastric emptying effects
of pramlintide were compared in individuals with type
1 or type 2 diabetes, they were determined to be
equally effective. Likewise, in volunteers without
diabetes, pramlintide delayed gastric emptying with-
out affecting small bowel or colonic transit (Samsom
et al., 2000). Hence, the effects of amylin agonism on
gastric emptying have been recapitulated in the clinic
and are evident irrespective of disease state.
B. Obesity
The studies summarized in section V indicate that
amylin physiologically contributes to the control of
eating, energy expenditure, and body weight. On the
basis of these actions, it could be hypothesized that
reduced amylin secretion, action, or sensitivity may
contribute to less satiation, increased meal sizes and
overall eating, and lower energy expenditure, together
eventually contributing to the development of obesity.
1. Amylin Secretion in the Obese State. Although
regulation of amylin secretion has not been extensively
evaluated in humans, there is some evidence for
elevation of amylin in the obese state (Ludvik et al.,
1991; Enoki et al., 1992; Hanabusa et al., 1992;
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Blackard et al., 1994; Kautzky-Willer et al., 1994; Roth
et al., 2010; Lee et al., 2011; Jacobsen et al., 2012).
Plasma levels appear to reach up to approximately
twice those achieved in nonobese subjects, but whether
this results overall in sustained levels of amylin in
excess of those that would be achieved postprandially is
not clear. A study of amylin (and other hormones) in
obese (n = 16) compared with control (n = 14) adolescent
subjects showed elevated fasting amylin levels, along-
side insulin resistance. In response to a test meal,
amylin levels increased to a greater degree in the obese
subjects compared with control subjects (Beglinger
et al., 2014). A study by Jacobsen et al. (2012) evaluated
hormonal changes in patients before and after bariatric
surgery. In that study, there was an observed di-
vergence of relationship between insulin and amylin in
which insulin increased significantly postsurgery where
amylin levels were unchanged. A study by Blackard
et al. (1994) looked at the hormonal response in nine
morbidly obese subjects via portal vein sampling at the
time of bariatric surgery. Their data collaborated the
concept of insulin and amylin being cosecreted; how-
ever, there was a lot of intersubject variation. Un-
fortunately, the clinical data to evaluate the secretion of
amylin are still very limited and the available data
should be used with caution due to the small number of
experimental subjects in many of the studies.
On the other hand, several lines of preclinical
research have produced hypothesis-generating data
that could translate well with respect to clinical
relevance. Previous data had indicated that baseline
amylin levels may be higher in obesity (Pieber et al.,
1994), but it was not clear whether the meal-contingent
release of amylin was affected by high-fat diet exposure
and whether the postprandial release pattern differed
between obese and nonobese rats (Boyle et al., 2011).
Because the meal-induced rise in amylin levels is
thought to underlie the meal-ending effect of amylin
and other satiation hormones, and because the rele-
vance of higher fasting levels of satiation hormones for
the control of eating is not clear, this experiment
allowed us to test the hypothesis of whether a deficient
rise in amylin secretion in response to a meal may
contribute to overeating and ultimately the develop-
ment of obesity. Using the well described diet-induced
obese (DIO) rat model, we found that both high-fat diet
exposure and obesity influenced the meal-induced
amylin release (Boyle et al., 2011). Exposure to the
high-fat diet affected baseline amylin levels because
diet-resistant rats, which had a lower body weight than
low-fat (chow)–fed rats, had elevated baseline amylin,
and all rats on the high-fat diet demonstrated an
earlier meal-induced rise in plasma amylin compared
with the chow control group. Hence, in contrast with
our hypothesis, we did not observe any indication of
deficient amylin secretion in obesity or in the rats
exposed to the high-fat diets, suggesting that deficient
amylin secretion does not contribute to the develop-
ment of obesity, at least under the conditions tested
(Boyle et al., 2011).
In summary, although basal amylin levels may be
slightly elevated, a meal-induced rise in plasma amylin
is still observed in the obese state, indicating that there
is no major impairment in secretion. However, more
work is needed to determine whether there are more
subtle differences in absolute amount of amylin re-
leased and whether there are long-term effects of diet
on the patterns of amylin secretion.
2. Amylin Sensitivity in the Obese State. A well
described phenomenon in obesity is the development of
resistance to the eating-inhibitory effects of exogenous
leptin and insulin, as well as to meal-related signals
like CCK and GLP-1 or their agonists (Deacon and
Ahrén, 2011; Zhou and Rui, 2013). Leptin insensitivity
has typically been documented by reduced induction of
pSTAT3, an intracellular signaling molecule that is
instrumental in mediating leptin function (Wauman
and Tavernier, 2011). The decreased pSTAT3 response
in leptin target neurons correlates with a reduced
eating-inhibitory effect of leptin. Obesity may also
reduce insulin and leptin transport into the brain by
affecting the blood–brain barrier permeability (Banks,
2006). Finally, hyperleptinemia itself, which develops
as a consequence of reduced sensitivity to leptin in
obesity, seems to further reduce the animals’ sensitiv-
ity to the action of leptin (Zhang and Scarpace, 2006).
Similar to the question above, we recently investi-
gated whether reduced sensitivity to amylin’s effects
on eating or energy expenditure may contribute to the
development of obesity. In other words, we wanted to
know whether amylin action may also be affected by
obesity or the chronic intake of diets high in fat (Boyle
et al., 2011). First, we found no evidence that rats that
were chronically maintained on a high-fat diet would
reduce the rats’ sensitivity to acute amylin. The intake
of a high-fat diet alone did not seem to markedly alter
amylin sensitivity; despite a slight attenuation of the
animals’ response to acute amylin after many months
on the high-fat diet, amylin sensitivity was not lost
completely (Boyle et al., 2011). Second, although
amylin transport across the blood–brain barrier has
been described (Banks and Kastin, 1998), this trans-
port may not be necessary for many AP-mediated
central amylin actions because the AP is devoid of
a blood–brain barrier. Hence, even if reduced amylin
transport across the blood–brain barrier occurred in
obesity (which has not been tested), the relevance of
this phenomenon would probably be minor.
Third, we tested whether chronic increases in
plasma amylin could be a cause of reduced amylin
sensitivity in obese rats. Because hyperleptinemia
seems to be required for the full development of leptin
resistance in rats (Knight et al., 2010), and because
increased circulating levels of CCK are implicated in
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a reduced sensitivity to CCK (Covasa et al., 2001), we
tested whether elevated circulating baseline amylin
may decrease the sensitivity to acute exogenous
amylin administration. However, we observed that
amylin acutely decreased eating to a similar extent in
all rats and regardless of circulating amylin levels
(Boyle and Lutz, 2011; Boyle et al., 2011). Hence, at
least under the experimental conditions of our study,
a decrease in the sensitivity to the eating-inhibitory
effect of acute amylin was not apparent and a down-
regulation of amylin receptors or a decrease in
postreceptor signaling after hyperamylinemia there-
fore appeared to be unlikely.
Finally, we tested whether exposure to highly palat-
able diets like Ensure nutrition shakes (Abbott
Nutrition, Columbus, OH; Wielinga et al., 2010)
acutely changed amylin sensitivity. We found that at
least temporarily, acute exposure to palatable choco-
late Ensure reduced the eating-inhibitory effect in-
duced by acute central or peripheral amylin. However,
high doses of central amylin were still active, suggest-
ing that rats had not become completely amylin
insensitive (Wielinga et al., 2010). In another study,
amylin or salmon calcitonin may be less potent in
models of reduced leptin sensitivity (or signaling) but
not in DIO models. Salmon calcitonin could effectively
inhibit food intake in DIO animals with functional
leptin resistance (Eiden et al., 2002).
To summarize, reduced amylin sensitivity is ob-
served only under some experimental conditions. In
contrast with leptin resistance, where central leptin
receptor function seems to be compromised, particu-
larly in its presumed primary sites of action in the
arcuate nucleus and VMH, amylin receptor function in
the AP was similar in lean chow-fed or obese rats with
diet-induced obesity. Hence, amylin insensitivity may
not be caused by direct changes in amylin receptor
function, but tests whether intracellular signaling
systems like cGMP and pERK (Riediger et al., 2001;
Potes et al., 2012) are affected by body adiposity or diet
composition still need to be done. Although decreased
leptin transport across the blood–brain barrier appears
to play a role in leptin resistance (Banks, 2006), such
an effect is unlikely to be of relevance for amylin.
Finally, rats with elevated plasma amylin seem to be
fully responsive to acute amylin injections. Overall, our
results suggest that reduced amylin sensitivity may
not be a prominent feature contributing to the de-
velopment of obesity; however, there has been little
investigation of this in human obesity.
3. Food Intake and Body Weight: Preclinical Studies
in Diet-Induced Obese Rat Models. DIO-prone rats
exhibit many characteristics of human obesity (in-
creased fat mass, obesity-related disturbances such as
dyslipidemia and hyperinsulinemia) and lack genetic
disruption of key feeding-related central signal-
ing pathways (Levin and Dunn-Meynell, 2000).
Importantly, the anorexigenic effects of peripheral
amylin, which were largely demonstrated in acute
tests in lean animals, translated into meaningful
weight loss in these models (Roth et al., 2006). In
DIO rats, peripherally administered rat amylin (3–
300 mg/kg per day) for 4 weeks reduced food intake and
decreased body weight by 10%–14% at the highest
doses tested. Pair-feeding studies revealed some
important differences between amylin-induced weight
loss compared with that induced by caloric restriction
alone (Roth et al., 2006). Although food intake re-
duction was the predominant mode of action for overall
weight loss, the composition of weight loss was notably
different across treatment groups. In amylin-treated
rats, weight loss was entirely attributable to reduc-
tions in fat mass, with relative preservation of lean
mass. By contrast, pair-fed control animals experi-
enced reductions in both fat and lean body mass.
Amylin-induced weight loss was also demonstrated to
not be associated with counter-regulatory decreases in
energy expenditure typically associated with a reduced
weight state. When amylin’s weight- and fat-reducing
properties were evaluated across a variety of nutritive
states, they were determined to still be evident after
a diet “lead-in” regimen (Roth et al., 2007a; Wielinga
et al., 2010). Finally, amylin monotherapy remained
similarly effective at reducing body weight irrespective
of starting body weight; in other words, there does not
appear to be “amylin resistance” to the weight-lowering
actions of amylin with increasing obesity (reviewed in
Lutz, 2012b).
At this point, it is important to mention that in many
studies with rats or mice mentioned here or elsewhere
in this review, amylin treatment resulted in a sig-
nificant reduction in (vehicle-corrected) body weight
compared with control animals; however, amylin-
treated animals may still have exhibited a gain in
absolute body weight, albeit less than in controls. One
may, therefore, argue that this effect is not sufficient
for a clinically relevant action. There is, however,
a critical difference between rodents and humans in
this respect—that is, most rat and mouse strains keep
gaining body weight more or less throughout their
entire life span. Furthermore, amylin-induced decreases
in absolute body weight (true weight loss) have been
reported in weight-stable rats (retired female breeders)
(Roth et al., 2007a).
C. Identifying Amylin Agonist-Responsive Populations
in Preclinical Models
With the arsenal of available therapies for metabolic
diseases continuing to evolve, it is likely that sub-
groups of target populations will exhibit differential
responsiveness to any given pharmacological agent.
Just as large differences in the regulation of energy
homeostasis exist between males and females, it is not
unreasonable to assume that therapeutic modalities
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will be more, or less, efficacious as concentrations of
gonadal hormones fluctuate during development and
aging. Sexually dimorphic effects are especially rele-
vant with respect to neurohormone-based therapies for
metabolic diseases, because pharmacological and neu-
robiological studies have convincingly demonstrated
a role for estradiol in the central control of energy
balance. These studies generally predict that the
presence of estradiol enhances the anorexigenic prop-
erties of short-term signals of satiation (e.g., CCK)
and long-term signals of adiposity (e.g., leptin), while
concomitantly decreasing the potency of orexigenic
signals (e.g., melanin concentrating hormone, neuro-
peptide Y, ghrelin; reviewed in Asarian and Geary,
2006; Brown and Clegg, 2010; Butera, 2010). We
recently explored whether estradiol signaling affected
the weight regulatory and metabolic effects of amylin
agonism (see also Fig. 5) (Trevaskis et al., 2010c). We
observed a surprising approximately 2-fold increase in
amylin’s weight-lowering efficacy in a state of estradiol
deficiency [DIO ovariectomized (OVX) rat model]
compared with sham-operated controls. Detailed met-
abolic studies revealed that amylin reversed the de-
cline in energy expenditure and fat oxidation linked
to an estradiol-deficient state via food intake–
dependent (reduction in respiratory exchange ratio)
and food intake–independent (maintenance of meta-
bolic rate) mechanisms. Because postmenopausal
women comprise a large majority of patients for whom
weight loss agents are prescribed, the extent to which
these preclinical observations translate into the clini-
cal use of the amylin agonist pramlintide warrants
further investigation. These studies should also com-
prise detailed mechanistic experiments that clarify the
apparent paradox that while under chronic conditions,
the lack of estradiol enhances amylin action, but
exogenous and endogenous amylin were more effective
when given acutely to OVX rats that received physi-
ologic estrogen replacement therapy (Asarian et al.,
2011).
Interestingly, an antidepressive and neurogenic
profile of amylin agonism was also noted in these
studies. First, amylin restored neurogenesis in the
hippocampus of OVX rats and increased (approxi-
mately 2-fold) neurogenesis within the AP. These
alterations were not evident in sham rats treated with
amylin. Amylin-treated OVX rats also displayed de-
creased immobility (i.e., improvements in this de-
pressed phenotype) compared with sham-operated
controls in the forced swim test. These findings
warrant further exploration but they are noteworthy
because estradiol concentrations decrease in postmen-
opausal women, who make up a high percentage of the
obese population, and incidences of depression are
reported to be increasing during menopause (Asarian
and Geary, 2006). To what extent amylin agonism may
hold utility in neurodegenerative diseases remains to
be elucidated. Collectively, these preclinical findings
raise the intriguing possibility that the integrated
mechanisms of amylin may improve metabolic and
behavioral processes and represent an important area
for future clinical research.
D. Next-Generation Drugs for the Amylin System
Pramlintide is a useful mimetic of human amylin but
other amylin agonists with improved potency and
pharmacokinetics may provide optimized therapeutics
for the treatment of obesity. Several additional analogs
of human amylin have been synthesized and investi-
gated. The feasibility of orally administered amylin has
also recently been explored. There are also alternative
approaches that could be used, such as inhibition of
amylin degradation.
1. Davalintide. Davalintide is an amylinomimetic
that showed significantly enhanced potency, efficacy,
duration of action, and pharmaceutical properties for
producing weight loss in rodent models (Mack et al.,
2010). Davalintide is a 32-amino-acid peptide that
shares 49% identity to rat amylin and pramlintide, and
it is a chimera of amylin and salmon calcitonin (Fig. 3).
Davalintide displays similar in vitro binding affinity to
rat amylin in a rat amylin/calcitonin receptor prepa-
ration (nucleus accumbens), 10-fold greater affinity
compared with rat amylin at the human CGRP
receptor (SK-N-MC cells), and 100-fold greater affinity
than rat amylin at the rat calcitonin receptor (trans-
fected HEK293 cells). Davalintide and amylin showed
comparable potency to activate cAMP production in
RINm5F cells (Mack et al., 2010). A direct comparison
between the pharmacology of davalintide, salmon
calcitonin, and amylin at defined calcitonin and amylin
receptor subtypes would be informative to provide
deeper understanding of the molecular properties of
this peptide.
In satiated rats, davalintide significantly reduced
food consumption up to 23 hours after injection. By
contrast, at an equivalent dose, rat amylin signifi-
cantly decreased food intake only from 1 to 3 and 5 to
6 hours after treatment. In DIO rats, sustained davalin-
tide infusion dose-dependently decreased food intake,
body weight, and fat mass to a greater extent than that
observed with rat amylin. In general, davalintide
exhibited greater duration of action, approximately
10-fold greater potency to reduce food intake, and
2-fold greater efficacy to reduce body weight compared
with rat amylin in rats. With respect to effects on food
preference, consumption of a high-fat (palatable) diet
was significantly reduced by davalintide and amylin
compared with control animals. Both davalintide and
amylin reduce eating by an AP-mediated mechanism
and both activate similar brain nuclei, with davalin-
tide displaying an extended duration of c-Fos expres-
sion compared with amylin (8 versus 2 hours) (Mack
et al., 2010). Interestingly, these effects exceed those
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predicted by its pharmacokinetic profile [the half-life
of davalintide (200 mg/kg s.c.) was 26 minutes].
Analyses of receptor binding kinetics showed limited
dissociation from rat nucleus accumbens membranes
(Mack et al., 2011). This is not surprising, given that it
contains portions of the salmon calcitonin sequence;
salmon calcitonin is well recognized as having a slow
receptor dissociation rate from receptors (Hilton et al.,
2000). These findings suggest that it may be possible to
design amylinomimetics with a longer duration of action
that would require fewer daily injections. Glucoregulatory
actions of davalintide were also studied in rodents,
and this amylinomimetic peptide displayed similar but
more protracted actions versus rat amylin on glucose
lowering and suppression of gastric emptying (Mack
et al., 2011).
2. PEGylated or Glycosylated Amylin. Given the
short half-life of amylin, another strategy to improve
the molecule has been to improve its half-life through
the addition of molecular scaffolds such as polyeth-
ylene glycol (PEG). A recent preparation has been
described for the PEGylation of amylin (Guerreiro
et al., 2013). Subcutaneous administration of PEGylated
amylin in mice revealed the effectiveness of monoPEG-
amylin and diPEG-amylin in reducing glycemia, with
both compounds exhibiting prolonged action relative
to unmodified amylin (Guerreiro et al., 2013). Further
testing of these molecules is warranted. Several
pharmaceutical companies have also been investigat-
ing improving the pharmaceutical properties of pram-
lintide via either PEGylation or adding albumin
binding motifs (e.g., Amylin, Unigene, Novo Nordisk,
and AstraZeneca) to develop a daily or weekly injection
product (Hansen et al., 2007; Mehta et al., 2013).
Another strategy was recently employed in which
glycosylation of pramlintide was tested as a possible
means of enhancing half-life. The synthetic glycopep-
tides that were generated had in vitro and in vivo
activity, suggesting that this could be a useful ap-
proach for further investigation (Tomabechi et al.,
2013; Kowalczyk et al., 2014). Hence, there remains
strong interest in developing more patient-friendly
amylin agonist strategies for treatment of metabolic
diseases.
3. Oral Amylin Agonists. A few studies have shown
proof of concept for oral administration of amylin
agonists. Intravail (Aegis Therapeutics, LLC, San
Diego, CA) is a broad class of chemically synthesizable
transmucosal absorption enhancement agents. Pram-
lintide has been formulated in Intravail and after
administration to exert the expected effects on energy
balance and glycemic control in insulin-resistant male
C57BLK/6-m db/db mice (Leinung and Grasso, 2012).
Recent preclinical findings suggest that orally ad-
ministered salmon calcitonin may hold antidiabetic
and weight-lowering potential. Salmon calcitonin was
formulated in 5CNAC-sCT [N-(5-chlorosalicyloyl)-8-
aminocaprylicacid]. When given orally, 5CNAC-sCT
appears to be protected from upper digestive tract
proteases. This enables the complex to access the
higher pH environment in the upper small intestine
intact and then dissociate enabling improved systemic
absorption (reviewed in Karsdal et al., 2011). In DIO
rats, oral gavage of this formulation reduced glucose
and insulin area under the curve during an oral
glucose tolerance test, and weight-lowering effects in
various models have also been achieved (Feigh et al.,
2011, 2012). These findings highlight the potential for
oral delivery of amylin agonists rather than via
multiple daily injections. It remains to be seen whether
any of these formulations will be commercially feasible
or pharmaceutically developable from a cost-of-goods
and bioavailability perspective.
4. Inhibition of Amylin Degradation. Overall, sev-
eral strategies have been investigated to search for
novel amylin agonists that may possess more pharma-
ceutically and patient-friendly properties. However,
the strategy of inhibiting degradation of endoge-
nous amylin, as has been successfully used with the
dipeptidyl peptidase-IV inhibitors to enhance plasma
levels of endogenous active GLP-1 (Holst, 2004), has to
date not been evaluated for amylin peptides. Amylin’s
action is relatively short lived because of its short half-
life, and termination of amylin action seems to be mainly
due to renal metabolism and excretion (Leckström et al.,
1997; Vine et al., 1998a). Therefore, manipulation of
its degradation may not be a useful pharmacological
approach. Furthermore, the target plasma concentra-
tions required to produce significant glucose-lowering or
weight loss benefits in humans may be beyond that
which can be achieved solely via inhibition of peptide
degradation.
IX. Amylin Interactions: Physiology
and Pharmacology
A. Amylin and Leptin
The most extensively investigated amylin-based
combination is with the adipokine leptin (Fig. 6).
Leptin is regarded as the prototypical long-term signal
of energy balance; however, obese rodents and humans
are largely nonresponsive to exogenous leptin admin-
istration. Early studies demonstrated that acute third
ventricular leptin increased the eating-inhibitory effect
of peripheral amylin in lean rats (Osto et al., 2007).
Next, exogenous pharmacological amylin was shown to
synergize with peripherally administered leptin to
induce marked and sustained fat-specific body weight
loss in leptin-resistant DIO rats (Roth et al., 2008a;
Trevaskis et al., 2008). These findings suggested that
amylin may help restore leptin responsiveness in
obesity. The effects appear to be pharmacological in
nature; in other words, both agonists need to be
present for leptin’s pharmacological effects to be
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evident in obesity. DIO rats pretreated with amylin or
with the combination of amylin and leptin did not
maintain their weight loss when switched to a regimen
of leptin monotherapy (Roth et al., 2008a; Turek et al.,
2010). Studies exploring caloric restriction, surgery,
and coadministration of other anorexigens suggest that
amylin appears to be one of the best modalities for
restoring leptin responsiveness. Caloric restriction
alone does not appear to be sufficient to restore leptin
responsiveness in preclinical models or obese human
subjects. For example, rats pair fed and weight
matched to an amylin-treated group did not lose
additional weight when leptin was coadministered
(Roth et al., 2008a).
In terms of other pharmacologies, doses of PYY(3-36)
or an exenatide analog were selected that gave
a similar magnitude of weight loss (6%) that was
sufficient for amylin to restore leptin responsiveness
(Roth et al., 2008a). In these studies, only additive to
less than additive effects were observed. In line with
these findings, leptin replacement alone or with
exendin-4 failed to promote greater weight loss in
weight-reduced DIO rats (Reidelberger et al., 2012).
Although a leptin/exendin synergy has been reported
in DIO mice, it was only evident after an initial body
weight loss of 30% (Müller et al., 2012), far greater
than the 6% required for amylin/leptin synergy.
Mechanistic studies suggest that the presence of
Fig. 6. (A) Effect of amylin on body weight in DIO rats. Change in body weight (percent vehicle corrected) of rats receiving amylin (3–300 mg/kg per
day) for 4 weeks via subcutaneously implanted osmotic minipumps. Mean6 S.E.M. *P, 0.05 versus vehicle. (B) Effect of pramlintide in obese subjects.
Changes in body weight from baseline for placebo (n = 17), 120 mg pramlintide (n = 24), 240 mg pramlintide (n = 17), or 360 mg pramlintide (n = 21)
twice daily (evaluable population). Mean6 S.E.M. *P, 0.05; **P, 0.01 versus placebo. (C) Effect of amylin, leptin, or amylin plus leptin on body weight in
DIO rats. Change in body weight (percent vehicle corrected) of rats pretreated for 14 days with 100 mg/kg per day amylin and then maintained on
100 mg/kg per day amylin switched to either 500 mg/kg per day leptin monotherapy or 100 mg/kg per day amylin plus 500 mg/kg per day leptin combination
therapy (n = 6–8/group). Compounds were delivered for 6 weeks via subcutaneously implanted osmotic minipumps. Mean 6 S.E.M. *P , 0.05
versus vehicle; #P , 0.05, compared with monotherapies. (D) Effect of metreleptin, pramlintide, or metreleptin plus pramlintide combination on
body weight in obese subjects. Changes in body weight from enrollment (week 4) for subjects pretreated with pramlintide (titrated from 180 mg to
360 mg) twice and then treated with 360 mg pramlintide twice daily, 5 mg metreleptin twice daily, or pramlintide plus metreleptin combination
treatment (evaluable population, n = 93). Mean 6 S.E.M. #P , 0.05; ##P , 0.01; ###P , 0.001, compared with monotherapies. This figure has been
redrawn from the individual publications in which these data were presented. (A) contains data from Mack et al. (2010); (B) contains data from
Smith et al. (2008); and (C and D) are from Roth et al. (2008a).
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amylin “primes” the hypothalamus to respond to leptin
by enhancing leptin receptor number and/or signaling
capacity (for a recent review of the physiologic, neuro-
biological, and molecular mechanisms mediating these
interactions, see Trevaskis et al., 2010b). This may be
due to amylin increasing interleukin-6 expression (Le
Foll et al., 2015). It was recently reported that leptin
and amylin may also interact functionally in the VTA
(Mietlicki-Baase et al., 2015).
B. Amylin and PYY(3-36)
PYY is a 36-amino-acid peptide hormone that is
secreted from intestinal L cells after a meal and is
cleaved by dipeptidyl peptidase-IV to generate PYY
(3-36), the major circulating form (Grandt et al., 1994).
Experiments in rodents have shown that PYY(3-36)
inhibits food intake, reduces body weight gain, and
increases utilization of fat stores for energy. A series
of rodent studies examined the effects of combined
administration of amylin and PYY(3-36). Overall, these
studies revealed that amylin and PYY(3-36) together
were able to elicit a greater reduction in 24-hour food
intake after a single acute injection than either
monotherapy without significantly changing locomotor
activity. With sustained administration, the combina-
tion synergistically reduced food intake and additively
reduced body weight in DIO-prone rats (Roth et al.,
2007b).
C. Amylin and Cholecystokinin
CCK is a short-term satiation signal released from
intestinal L cells after nutrient consumption. After its
release, CCK is thought to exert a paracrine effect by
its actions on vagal afferents that project to the NTS.
CCK acutely synergizes with amylin to suppress food
intake in lean mice (Bhavsar et al., 1998; Mollet et al.,
2003a). To expand on these findings, sustained ad-
ministration studies (7 days) assessed whether the
combination of amylin and CCK would synergize for
weight loss in DIO rats. As expected, amylin treatment
induced significant body weight loss. CCK, although
ineffective alone, significantly enhanced body weight
loss when coadministered with higher doses of amylin.
c-Fos activation was also assessed in various brain
nuclei after a single intraperitoneal injection of amylin
and/or CCK. Amylin and CCK additively increased
c-Fos within the AP, predominantly in noradrenergic
(e.g., DBH-containing) cells.
D. Amylin and Melanocortins
An important downstream regulator of leptin is the
hypothalamic melanocortin (MC) system. Convergent
lines of evidence underscore the importance of the
melanocortin subtype-4 receptor (MC-4R) as a key
regulator of feeding behavior. The impact of impaired
MC signaling on amylin’s efficacy has been evaluated
in two species. Chow-fed overnight fasted agouti and
wild-type mice respond similarly to an acute dose of
amylin (Roth et al., 2006). However, MC-4R–knockout
mice displayed quantitatively reduced responsiveness to
salmon calcitonin at a dose range that was effective in
chow-fed C57Bl/6J mice (overnight fasted) (Eiden et al.,
2002), and Mc4rK314X/K314X rats were nonresponsive to
an acute dose of amylin that was effective in wild-type
rats. Overall, it is unclear whether amylin’s acute food
intake–lowering effects are MC-4R dependent (Roth
et al., 2012). One explanation for these discrepant
findings may be that these are two different models of
MC dysregulation; agouti mice are a model of ectopic
endogenous MC-3R/MC-4R antagonism (by agouti over-
expression), whereas the Mc4rK314X/K314X rat is a re-
ceptor loss-of-function model. The methodological and
procedural differences (e.g., species, diet composition,
nutritive status) across these different studies may
also play a role. Nevertheless, coadministration stud-
ies clearly demonstrate the antiobesity potential for
combined agonism of these MC and amylinergic
systems. Amylin coadministration enhanced the acute
food intake–lowering effects of Ac-R[CEH-dF-RWC]-
amide in mice and with repeated coadministration had
durable, additive anorexigenic, weight-lowering, and
fat-lowering effects in DIO rats (Roth et al., 2012).
E. Amylin and Glucagon-Like Peptide 1
Combined amylin and GLP-1 receptor agonism has
also been assessed (Bello et al., 2010). This study
evaluated the acute anorexigenic effects of coadminister-
ing the amylin/calcitonin receptor agonist salmon calci-
tonin alone and in combination with GLP-1 receptor
agonist exenatide in a non–human primate model.
Monkeys were maintained on a schedule of 6-hour daily
access to food and multiple dose combinations were
used. This experimental design enabled the authors
to use response surface methodology and test for statis-
tical additivity or synergy for suppression of food intake.
Synergistic anorexigenic effects were noted during
hours 1–4 and additive effects during hours 5 and 6.
Behavioral observations suggested that the monkeys
did not display malaise or nausea. After a washout
period, monkeys received repeated daily injections of one
of the dose combinations (0.56 mg/kg Exendin-4 + 0.32
mg/kg salmon calcitonin) for 5 days. During this phase of
the study, sustained reductions in daily food intake
(.70% from saline baseline) were noted for 5 days,
suggesting that the additive/synergistic effects of the
combination may be durable. Future repeated adminis-
tration studies should include monotherapy arms to give
a better sense for the potential additive/synergistic
potential of this combination.
F. Amylin and Small Molecule Anorectics
Amylin has also been combined with various classes
of small molecule anorectic agents that are either still
approved for the short-term treatment of obesity
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(phentermine), are withdrawn frommarket (sibutramine),
or are in late stages of regulatory review (naltrexone/
bupropion). These studies are reviewed below.
Phentermine is a b-phenethylaminic derivative that
acts through monoaminergic systems (noradrenaline
and dopamine) to decrease food intake and body weight.
Sibutramine inhibits the reuptake of central noradren-
aline and serotonin and stimulates thermogenesis in
rodents. Mathematically additive food intake, weight-
lowering, and fat-lowering effects were observed when
amylin was combined with either phentermine or
sibutramine. Detailed analyses of feeding patterns with
amylin and phentermine suggest that these effects may
be achieved by an approximately 2-fold increase in the
satiety ratio compared with either agent alone (Roth
et al., 2008c). In terms of off-target behavioral effects,
amylin neither enhanced nor reduced the known actions
of phentermine (which is an amphetamine derivate) to
stimulate activity (Roth et al., 2008c).
Antagonism of opioid systems (e.g., with naltrexone) is
another antiobesity strategy, and it is particularly
effective when coadministered with dual inhibitors of
dopamine and norepinephrine reuptake (e.g., bupropion).
The interaction of amylin with naltrexone/bupropion on
energy balance has recently been explored (Clapper
et al., 2013). Wild-type and amylin knockout mice were
similarly responsive to the food intake–lowering effects
of either naltrexone (1 mg/kg s.c.) or bupropion (50 mg/kg
s.c.), suggesting that they act independently of amyli-
nergic systems and could interact additively when given
in combination with amylin. To test this, DIO rats were
treated (for 11 days) with vehicle, rat amylin (50 mg/kg
per day s.c.), naltrexone/bupropion (1 and 20 mg/kg,
respectively, by twice-daily s.c. injection), or their com-
bination. Amylin plus naltrexone/bupropion combination
therapy exerted additive effects to reduce cumulative
food intake, body weight, and fat mass. In a separate
study, the effects of amylin and naltrexone/bupropion
administered at the same doses (for 14 days) were
compared with a pair-fed group. Although the combi-
nation and pair-fed groups lost a similar amount of body
weight, rats treated with the combination lost 68% more
fat and better maintained their lean mass. These
findings support the strategy of combined amylin
agonism with opioid and catecholaminergic signaling
systems for the treatment of obesity.
X. Amylin in Clinical Studies
This section covers many of the major clinical studies
of amylin/pramlintide. In some places, we also describe
relevant preclinical studies to aid in understanding
how translatable these findings were to the clinic.
A. Pharmacology of Amylin Agonists
Pramlintide is a synthetic and equipotent analog of
human amylin and is used as an adjunctive therapy to
patients treated with mealtime insulin. It differs from
the natural peptide by three amino acids; prolines were
substituted at positions 25, 28, and 29 (Fig. 3). These
substitutions were necessary to overcome several
physicochemical properties that make human amylin
unsuitable for pharmacologic delivery, including poor
stability in solution and a propensity to aggregate
and adhere to surfaces. Hence, amylin’s biology and
therapeutic potential in humans is almost exclusively
assessed using pramlintide. By contrast, reports on the
actions of amylin in rodents have been assessed using
either rat amylin (which also possesses favorable
pharmaceutical properties) or pramlintide. In general,
the pharmacological and pharmacokinetic properties of
pramlintide are identical to those of rat amylin, when
the two peptides are compared in preclinical rodent
models (Young et al., 1996b).
The pharmacokinetics of pramlintide in rats reflects
a half-life of approximately 13 minutes after intrave-
nous injection, a value identical to that of rat amylin
(Young et al., 1996b). A similar profile is seen with
intravenous injection of human amylin into normal
human males (Clodi et al., 1998).With subcutaneous
injection in rodents, half-lives for both rat amylin
and pramlintide are in the range of 15–35 minutes,
whereas bioavailability ranged between 25% and
40%. In normal humans, subcutaneous injections of
pramlintide ranging from 300 to 10,000 mg produced
half-life values varying from 26 to 42 minutes
(Moyses et al., 1993). In subjects with type 1 and type
2 diabetes, subcutaneous doses ranging from 30 to
180 mg gave similar profiles, with maximal plasma
concentrations achieved in approximately 20 minutes
and a half-life of around 50 minutes (Colburn et al.,
1996; Weyer et al., 2001). Two recent articles can be
consulted for more information on the pharmacoki-
netics of pramlintide (Younk et al., 2011; Fang et al.,
2013).
B. Clinical Studies Relating to Diabetes
Collectively, multiple clinical studies in insulin-
using patients with type 1 and type 2 diabetes suggest
that pramlintide addresses important deficits in the
treatment of diabetes, and pramlintide in combina-
tion with insulin may provide a more physiologically
balanced therapeutic approach (Younk et al., 2011).
A 2011 review of the literature pertaining to the clinical
data for the use of pramlintide in diabetes covers most
of these studies in some depth (Younk et al., 2011). In
brief, pramlintide treatment improved hemoglobin
A1c, reduced postprandial glucose excursions relative
to insulin therapy alone, enabled reductions in meal-
time insulin dosing, inhibited postprandial glucagon
secretion, and improved overall glycemic control.
Although excess weight gain is associated with many
antihyperglycemic therapies and can potentially in-
duce further insulin resistance, pramlintide treatment
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was associated with sustained and significant weight
loss. This aspect was apparent without prescribed dietary/
lifestyle interventions and is explored in more detail
below. Nausea (mild to moderate) is the most frequently
reported adverse event for pramlintide, yet the weight
loss experienced with pramlintide is largely indepen-
dent of any reported nausea.
Pramlintide was approved in the United States as an
adjunct therapy to mealtime insulin. The subcutane-
ous dose of pramlintide is fixed with 60 mg for patients
with type 1 diabetes and 120 mg for patients with type
2 diabetes, and patients are instructed to dose
pramlintide 30 minutes before a meal (Janes et al.,
1996; Center for Drug Evaluation and Research
Approval Package for Application Number 21-332.
Clinical Pharmacology and Biopharmaceutics Review.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/
21-332_Symlin%20Injection_biopharmr.pdf). Given the
fact that pramlintide is delivered as a separate in-
jection to mealtime insulin, compliance for patients
may be an issue. One study in patients with type 2
diabetes evaluated the addition of pramlintide versus
mealtime insulin as an adjunct to basal insulin to
reduce the injection burden and the clinical effect of
pramlintide without mealtime insulin. The results
showed that pramlintide was similar to rapid-acting
mealtime insulin with glycemic reduction but with less
hypoglycemia and no weight gain (Riddle et al., 2009).
In patients with type 1 diabetes, not only is com-
pliance an issue, but these patients are also more
prone to insulin-induced hypoglycemia. Few studies
have looked at ways to make the combination easier
and potentially safer for this population. One study
showed that acute mixing of pramlintide with rapid-
acting or basal insulin did not significantly alter the
pharmacokinetics and clinical effectiveness of pram-
lintide; however, there are no long-term mixing stud-
ies to assess the stability of both molecules (Weyer
et al., 2005). Insulin-induced hypoglycemia is the most
serious complication when using pramlintide with
mealtime insulin in the type 1 diabetes population.
Anecdotally, clinicians have reported that dosing
analog insulin before meals in conjunction with
pramlintide leads to more hypoglycemia because
patients underestimate the satiety effect of pram-
lintide and end up overdosing the mealtime insulin.
Given this, some clinicians have started dosing
mealtime insulin after the meal rather than before
the meal. Although it has not yet been officially ex-
amined, we can see this trend with some of the clinical
trial designs for patients with type 1 diabetes using
pramlintide as an adjunct to mealtime insulin (Hassan
and Heptulla, 2009).
Because more patients with type 1 diabetes are
using pump therapy, investigators have looked at
different ways of delivering the mealtime insulin dose
in conjunction with pramlintide. Two separate studies
have been conducted to evaluate how best to dose
insulin in a patient using pump therapy, in conjunction
with pramlintide. One study tested four different
insulin delivery wave forms: standard, square wave,
combination (standard shifting to square), and modi-
fied combination (standard combined with square
1 hour into the meal). In that study, it was found that
the square and modified combination was the safest
way to deliver insulin (King, 2010). Another study
found that a square wave delivery for patients with
type 1 diabetes near normal control was the best bolus
approach, whereas with weight loss, there may need to
be adjustments to total basal insulin dose to avoid
hypoglycemia (King, 2009).
Amylin and insulin are colocated and cosecreted in
a fixed molar ratio from the pancreatic b-cells; therefore,
amylin is also secreted in a basal-bolus fashion.
However, in clinical practice, insulin is often titrated
for clinical effect, whereas pramlintide is delivered in
a fixed dose and only at mealtime. Few studies have
evaluated the effect of pramlintide delivered in a basal-
bolus fashion. A 24-hour infusion study evaluating
pramlintide with insulin basal-bolus infusion versus
insulin infusion alone found that there was a significant
decrease in postprandial glycemic control and robust
glucagon suppression (Heptulla et al., 2009). Given the
exploratory nature of this study, the pramlintide dose
was calculated based on previous experience but had to
be changed during the study. Another pilot study
evaluated the pramlintide basal-bolus concept over
a 16-week period. The basal pramlintide rate was
9 mg/h and the bolus dose was administered per label
up to 60 mg/bolus at mealtime. The study showed
significant glucose, insulin dose, and weight reduction
but an increase in mild hypoglycemia (Huffman et al.,
2009). A real-world pilot study with a small cohort of
patients with type 1 diabetes (n = 5) and patients with
type 2 diabetes (n = 5) with variable duration of diabetes
and variable pramlintide to insulin ratios over a span of
1–5 years found that delivery of pramlintide in
a separate pump in a basal-bolus fashion resulted in
improved glycemic control, insulin dose reduction, and
weight loss (Schorr and Ofan, 2012). Therefore, there
may be some alternative dosing strategies that are
possible for pramlintide in patients with diabetes,
beyond current recommendations.
Given its physiologic actions and its clinical profile,
pramlintide is an attractive candidate as an additional
therapy to be included in the artificial pancreas in the
treatment of type 1 diabetes. Excessive glycemic
variability and hypoglycemia are major obstacles in
the development of an artificial pancreas. A study
evaluated dosing of 30 mg pramlintide bolus under
a closed loop system and showed that pramlintide not
only delayed the time to peak of postprandial hyper-
glycemia, but it also significantly reduced the glycemic
excursion (Weinzimer et al., 2012). There are currently
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no data to indicate the optimal pramlintide to insulin
ratio. Most of the studies done thus far tested variable
ratios in combination with a fixed dose bolus. At the
time of this writing, there is an active pilot study being
conducted by the Juvenile Diabetes Research Founda-
tion to evaluate the optimal insulin to pramlintide
ratio in the clinical setting (ClinicalTrials.gov identi-
fier NCT01708044: http://www.clinicaltrials.gov/ct2/
show/NCT01708044?term=pramlintide&rank=13). Al-
though much work has been done, more studies are
still needed to evaluate the role of pramlintide in an
artificial pancreas.
C. Clinical Studies Relating to Food Intake, Satiation,
and Weight Loss
The aforementioned observation that pramlintide
reduced body weight in patients with insulin-treated
diabetes, a patient population that generally suffers
from weight gain due to insulin, pointed to its potential
clinical utility as an antiobesity agent (Chapman et al.,
2005; Aronne et al., 2007). In clinical studies in obese
subjects, the weight-reducing effects of pramlintide
emerged as significant, sustained, and dose dependent
(Hollander et al., 2004; Smith et al., 2008; Singh-
Franco et al., 2011). Interestingly, weight loss occurred
despite the fact that subjects were instructed to
maintain their usual diet and exercise routines. Pro-
gressive weight loss was also seen in those subjects
who did not report nausea, providing further evidence
that the weight-lowering effect of pramlintide is
dissociable from the occurrence of nausea. The use of
pramlintide alongside lifestyle intervention resulted in
weight loss and enhanced long-term maintenance of
weight loss in obese subjects.
Weight loss is likely to be linked with the food
intake–lowering effects of pramlintide, which have
been demonstrated by several clinical studies in obese
subjects. A single injection of pramlintide 1 hour before
a buffet meal decreased food intake by 16% compared
with placebo (Smith et al., 2007). Pramlintide also
elicited an increase in satiety scores, despite the
consumption of less food. This indicates that less food
was required to promote meal-related satiation. In
other studies, pramlintide reduced total daily food
intake (by 15%–20%) in obese subjects when measured
both early during the study as well as after 6 weeks of
administration (Chapman et al., 2005, 2007). Pramlin-
tide was also shown to cause acute and sustained
reductions in the intake of high-fat and high-sugar
foods at a “fast-food challenge” and to improve
perceived control of eating, as demonstrated by a 45%
placebo-corrected reduction in binge eating scores
(Smith et al., 2007). These findings suggest that the
nuances of changes in feeding behavior (e.g., decreased
meal size while concomitantly increasing satiation,
reduced intake and preference for high-fat and high-
sugar foods), many of which are observed in preclinical
models with amylin, may also be recapitulated in the
clinic with pramlintide.
Pramlintide was evaluated in conjunction with
lifestyle intervention in a phase 2b dose-ranging
proof-of-concept study (Smith et al., 2008). Subjects
who entered the study were obese [body mass index
[BMI] $ 30 and # 50 kg/m2 for at least 1 year]
nondiabetic men and women aged 18–70 years with
abdominal obesity [waist circumference .102 cm for
men and .88 cm for women]. In this 4-month, double-
blind, placebo-controlled, dose-ranging study, 411
obese subjects were randomized to receive pramlintide
(six arms: 120, 240, and 360 mg twice daily and three
times daily) or placebo in conjunction with a structured
lifestyle intervention program geared toward weight
loss. At the end of 4 months, 77% of the evaluable
subjects (n = 270) opted to continue preexisting
treatment during an 8-month single-blind extension
with lifestyle intervention geared toward weight
maintenance. At month 4, mean weight loss from
baseline in the pramlintide arms ranged from 3.8 6 0.7
to 6.1 6 0.8 kg (2.8 6 0.8 kg with placebo). By month
12, initial four-month weight loss was regained in the
placebo group but was maintained in all but the 120 mg
twice-daily group. Placebo-corrected weight loss with
120 mg three times daily and 360 mg twice daily
averaged 3.2 6 1.2 kg (3.1% 6 1.1% body weight) and
3.36 1.1 kg (3.1%6 1.0% body weight), respectively, at
month 4 (both P , 0.01; 4-month evaluable n = 270)
and 6.1 6 2.1 kg (5.6% 6 2.1% body weight) and 7.2 6
2.3 kg (6.8% 6 2.3% body weight), respectively, at
month 12 (both P , 0.01; 12-month evaluable n = 146).
At month 12, 40% and 43% of subjects treated with
120 mg three times daily and 360 mg twice daily,
respectively, achieved $10% weight loss (versus 12%
for placebo). Nausea was the most common adverse
event with pramlintide in the 4-month study (9%–29%
pramlintide versus 2% placebo) and it was generally
mild to moderate and occurred in ,10% of subjects
during the extension. Collectively, these studies sug-
gest that obese subjects treated with pramlintide alone
or as an adjunct to lifestyle intervention can achieve
weight loss and enhanced long-term maintenance of
weight loss. Fig. 6 compares preclinical and clinical
data for pramlintide-induced effects on body weight.
Davalintide has also undergone limited clinical
investigation. Translational medicine studies revealed
suppression of 24-hour food intake in obese humans
treated with davalintide (Nicandro et al., 2008).
D. Clinical Combination Studies (Metreleptin and
Small Molecules) Relating to Weight Loss
Obesity is a multifaceted disease. There are multiple
and redundant pathways to avoid weight loss as
a means of survival. Monotherapy for obesity, although
initially effective, often only yields modest and unsus-
tained weight loss. As with other chronic diseases such
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as hypertension, cancer, and diabetes, combinatorial
approaches have gained significant traction for the
potential treatment of obesity (Kim et al., 2013).
Analogous to diabetes, monotherapy-based approaches
for obesity target only a single aspect of a multi-
hormonal disease state. Although it was taken off the
market for safety reasons, the history of fenfluramine/
phentermine demonstrated that by targeting more
than one single pathway in the control of weight,
a robust and sustainable weight loss can be achieved.
Accordingly, a series of translational research studies
have demonstrated the potential utility of combined
amylin agonism with small molecule anorexigenic
agents (e.g., phentermine or sibutramine) or with an
analog of the long-term adiposity signal leptin (e.g.,
metreleptin) that may be useful in overcoming these
adaptations to promote meaningful weight loss. These
preclinical studies are described in section IX. Some
clinical investigation has also been conducted.
As discussed above, the neurohormonal control of
body weight involves a complex interplay between long-
term adiposity signals (e.g., leptin), and short-term
satiation signals (e.g., amylin). We have discussed that
in DIO rodents, amylin/leptin combination treatment
led to marked, synergistic, fat-specific weight loss (Fig. 6).
To evaluate the weight-lowering effect of combined
amylin/leptin agonism (with pramlintide/metreleptin)
in human obesity, a 24-week, randomized, double-blind,
active drug–controlled, proof-of-concept study was con-
ducted in obese or overweight subjects (n = 177; 63%
female; aged 396 8 years; BMI 32.06 2.1 kg/m2; weight
93.3 6 13.2 kg; mean 6 S.D.) (Ravussin et al., 2009).
The study started with a 4-week lead-in period for the
titration of pramlintide and dietary intervention. After
the initial lead-in period with pramlintide (180 mg twice
daily for 2 weeks, 360 mg twice daily thereafter) and diet
(40% calorie deficit), subjects achieving 2%–8% weight
loss were randomized 1:2:2 to 20 weeks of treatment
with metreleptin (5 mg twice daily), pramlintide (360 mg
twice daily), or pramlintide/metreleptin (360 mg/5 mg
twice daily). Combination treatment with pramlintide/
metreleptin led to significantly greater weight loss from
enrollment to week 20 (212.7% 6 0.9%; least-squares
mean6 S.E.) than treatment with pramlintide (28.4%6
0.9%; P , 0.001) or metreleptin (28.2% 6 1.3%; P ,
0.01) alone (evaluable, n = 93). The greater reduction in
body weight was significant as early as week 4, and
weight loss continued throughout the study, without
evidence of a plateau even at the 24-week end point. The
most common adverse events with pramlintide/metreleptin
were consistent with the two molecules studied
and were mainly injection site events and nausea,
which were mostly mild to moderate and decreased over
time. These results further support the concept that
combination treatment that targets separate physio-
logic pathways is a viable approach for the induction
of clinically meaningful weight loss.
A functional magnetic resonance imaging study
recently compared activation after the administration
of metreleptin with the combination of metreleptin
with pramlintide. Pramlintide significantly potenti-
ated leptin activation in mesolimbic brain regions such
as the hippocampus and amygdala (Klopfenstein et al.,
2010). To what extent these findings explain the weight
loss synergy between amylin and leptin agonism remains
to be determined.
Based on the preclinical finding of amylin in
combination with small molecule oral medications like
phentermine or sibutramine, a proof-of-concept phase 2
human clinical study was conducted (Aronne et al.,
2010). This study was a randomized placebo-controlled
trial, and it examined the safety and efficacy of the
amylin analog pramlintide alone or in combination
with either phentermine or sibutramine. All patients
enrolled in the study also received lifestyle interven-
tion. After a 1-week placebo lead-in period, 244 obese
or overweight subjects without diabetes (88% female;
41 6 11 years; BMI 37.7 6 5.4 kg/m2; weight 103 6
19 kg; mean 6 S.D.) received placebo (subcutaneously
three times a day), pramlintide (120 mg subcutane-
ously three times a day), pramlintide (120 mg sub-
cutaneously three times a day) plus oral sibutramine
(10 mg every day before noon), or pramlintide (120 mg
subcutaneously three times a day) plus oral phenter-
mine (37.5 mg every day before noon) for 24 weeks.
Treatment was single blind for subjects receiving
subcutaneous medication only and open label for
subjects in the combination arms. Weight loss achieved
at week 24 with either combination treatment was
greater than with pramlintide alone or placebo (P ,
0.001;211.1%6 1.1% with pramlintide plus sibutramine,
211.3% 6 0.9% with pramlintide plus phentermine,
23.7% 6 0.7% with pramlintide, 22.2% 6 0.7% with
placebo; mean 6 S.E.). Given that phentermine and
sibutramine all have potential to raise blood pressure
or heart rate, this cardiovascular safety parameter
was of particular importance in a population at higher
risk for cardiovascular events. Elevations in heart
rate and diastolic blood pressure from baseline were
demonstrated with both pramlintide plus sibutramine
(3.1 6 1.2 beats/min, P , 0.05; 2.7 6 0.9 mm Hg, P ,
0.01) and pramlintide plus phentermine (4.5 6 1.3 beats/
min, P, 0.01; 3.56 1.2 mmHg, P, 0.001) using 24-hour
ambulatory monitoring. However, the majority of subjects
receiving these treatments remained within normal blood
pressure ranges. These results validated the preclinical
observation that amylin agonism combined with another
pathway that targets weight management may have
additive or synergistic effects.
As we have stated before, obesity is a complex
disease and due to the evolutionary need for energy
preservation, there are multiple pathways to prevent
weight loss. Monotherapy in general does not elicit
the amount of weight loss patients and health care
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providers are looking for. The most robust clinical data
have come from combination therapies. However, the
development of small molecule obesity drugs has had
major safety issues in the past. The combination of
phentermine and fenfluramine was taken off the
market due to cardiac valvulopathy issues from
fenfluramine. The drug rimonabant that leverages
the cannabinoid pathway was also taken off the market
for suicidal risks. The most recent obesity therapy to be
taken off the market was sibutramine due to potential
increase in cardiovascular events. Despite these set-
backs, the U.S. Food and Drug Administration recently
approved another selective serotonin agonist like
fenfluramine called lorcaserin. As a monotherapy, it
elicits a modest weight loss of around 2 kg (Fidler et al.,
2011). Another therapy that was recently approved
was a combination of phentermine and topiramate.
Despite combining different pathways, the weight loss
was also modest and the highest dose did elicit the
most significant side effects (Gadde et al., 2011).
Despite new approvals, the obesity treatment land-
scape is still very limited due to potential safety
concerns (Kim et al., 2013). The recent U.S. Food and
Drug Administration approval of the GLP-1 receptor
agonist liraglutide for obesity (Saxenda; Novo Nordisk
Inc., Plainsboro, NJ) provides a new opportunity for
trialling combinations of pramlintide and liraglutide in
patients (Ladenheim, 2015). The attraction of leverag-
ing the physiologic pathway of amylin agonist is that it
can potentially deliver a more clinically meaningful
weight loss while minimizing the off-target adverse
events.
XI. Concluding Remarks
This review summarizes the tremendous increase in
knowledge about the physiology and pharmacology of
the pancreatic hormone amylin. As a member of the
CGRP family of peptides, amylin shares a large
number of biologic effects with calcitonin, CGRP, and
adrenomedullin. However, the effects of amylin in
particular in the control of energy homeostasis and its
current acceptance in the scientific community as
a short-term satiation factor clearly stand out and
have been the basis of many important physiologic and
clinical findings. Landmark studies in this area have
shown the following: 1) the first report that amylin
decreases eating in rats after central and peripheral
administration (Chance et al., 1991; Morley et al.,
1993); 2) that the caudal hindbrain and in particular
the AP is critically involved in the effects of amylin on
eating (Lutz et al., 1998c); 3) that amylin interacts with
other endogenous regulators of eating, in particular
with leptin, and that it overcomes leptin resistance in
obesity (Osto et al., 2007; Roth et al., 2008a); 4) that
amylin alone or in combination produces a clinically
relevant weight loss in humans (Smith et al., 2008;
Ravussin et al., 2009); and 5) some of amylin’s effects,
specifically amylin’s action to regulate the rate of
nutrient appearance in the blood, via slowing gastric
emptying and reducing postprandial glucagon secre-
tion, have already been translated into amylin-based
pharmacotherapy that has been introduced for many
years into clinical practice for the treatment of diabetes
mellitus.
Amylin was originally discovered as the main
component of islet amyloid deposition in patients with
type 2 diabetes. It soon became clear that amylin is
a physiologic secretion product of pancreatic b-cells
and that it is cosecreted with insulin. An important
breakthrough and surprising finding was the charac-
terization of the amylin receptor as a two-component
entity consisting of the calcitonin core receptor that
requires the coexpression of one of several RAMPs to
yield a specific amylin receptor (Christopoulos et al.,
1999; Muff et al., 1999). Although this concept is not
unique to the receptors of the CGRP family, it was
unexpected at the time of the discovery of the amylin
receptor. More than 20 years of research also let
amylin emerge as an important physiologic regulator of
meal size and perhaps of body weight. The brain
structures involved in this effect have been well
defined and the available data indicate that the amylin
signaling system seems to remain active in obesity
[i.e., under conditions when other signaling systems
(e.g., leptin) become defective]. The progress in preclinical
development was translated into the use of the amylin
analog pramlintide as an adjunct therapy to insulin for
patients with type 1 and type 2 diabetes, and the
weight-reducing potential of this approach compared
with insulin alone formed the basis for numerous
clinical trials utilizing amylin analogs and combination
therapies to combat obesity. Importantly, amylin is one
of the few established gut/pancreatic hormones that
has demonstrated durable, safe, tolerable, and clini-
cally meaningful weight loss in humans. Few drugs are
currently approved for the treatment of obesity and
these drugs typically produce weight loss of approxi-
mately 4%–7%, which is often below the expectations of
both patients and physicians and leads to underutili-
zation of these therapies. Available weight loss agents
and compounds in development are primarily small
molecule oral medications that alter neurotransmitter
levels. Because regulation of body weight appears to be
governed by complex interactions in the brain between
numerous centrally acting neurotransmitters, central
neuropeptides, and peptide hormones arising from the
periphery, combinations of agents targeted at distinct
regulatory pathways may produce additive or syner-
gistic effects on weight loss. In previously described
translational research studies, combinations of amylin
physiology with other hormones such as leptin have
revealed intriguing pharmacological synergies where
amylin appears to overcome the acquired resistance
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against the actions of leptin associated with weight
gain. Combination of amylin physiology with neurotrans-
mitter pathways such as phentermine and sibutramine
also yielded clinically significant weight loss by targeting
different pathways of weight control. As demonstrated
in both preclinical and clinical studies, amylin re-
ceptor agonism has emerged as a key component of an
integrated neurohormonal therapeutic approach for
weight reduction and maintenance that harnesses
synergies among several naturally occurring signals.
Hence, an amylin agonist has developed into a prom-
ising candidate for the pharmacological intervention
against obesity.
Future efforts should focus on deepening our un-
derstanding of amylin physiology with respect to the
mechanisms of amylin action in brainstem neurons but
also in other brain areas regulating reward behavior.
The detailed basis of the functional interaction of
amylin with other hormones, such as convergence of
signaling pathways, needs to be explored because this
may open new, more targeted treatment options
against obesity and other disorders. The particular
amylin receptor pharmacology with its specific struc-
ture as a two-component entity may offer additional
possibilities for direct manipulation of the amylin
signaling system with minimal side effects; the re-
ceptor subtype needs to be identified for each amylin
action. Finally, other potentially therapeutic effects of
amylin need to be explored in more detail because they
may form the basis for an extended use of amylin-
based pharmacotherapy for a large number of disor-
ders. Recent data have highlighted potential roles in
AD and for amylin as an antipsychotic. Further
characterization, clinical development, and subsequent
commercial availability of longer-acting (e.g., once-
weekly administration) amylin analogs should enhance
the acceptance of this important therapeutic target for
treatment of diseases including and beyond diabetes
and obesity.
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